<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xml:lang="en" article-type="research-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Int J Mol Sci</journal-id><journal-id journal-id-type="iso-abbrev">Int J Mol Sci</journal-id><journal-id journal-id-type="pmc-domain-id">808</journal-id><journal-id journal-id-type="pmc-domain">ijms</journal-id><journal-id journal-id-type="publisher-id">ijms</journal-id><journal-title-group><journal-title>International Journal of Molecular Sciences</journal-title></journal-title-group><issn pub-type="epub">1422-0067</issn><publisher><publisher-name>Multidisciplinary Digital Publishing Institute  (MDPI)</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC12429833</article-id><article-id pub-id-type="pmcid-ver">PMC12429833.1</article-id><article-id pub-id-type="pmcaid">12429833</article-id><article-id pub-id-type="pmcaiid">12429833</article-id><article-id pub-id-type="doi">10.3390/ijms26178618</article-id><article-id pub-id-type="publisher-id">ijms-26-08618</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>The Role of MCM7 and Its Hosted miR-106b-25 Cluster in Renal Cancer Progression</article-title></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0009-0002-8686-774X</contrib-id><name name-style="western"><surname>G&#322;uchowska</surname><given-names initials="KM">Katarzyna M.</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Conceptualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Methodology" vocab-term-identifier="https://credit.niso.org/contributor-roles/methodology/">Methodology</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Validation" vocab-term-identifier="https://credit.niso.org/contributor-roles/validation/">Validation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Formal analysis" vocab-term-identifier="https://credit.niso.org/contributor-roles/formal-analysis/">Formal analysis</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/">Investigation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Resources" vocab-term-identifier="https://credit.niso.org/contributor-roles/resources/">Resources</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Data curation" vocab-term-identifier="https://credit.niso.org/contributor-roles/data-curation/">Data curation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; original draft" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing &#8211; original draft</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; review &amp; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#8211; review &amp; editing</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Visualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/visualization/">Visualization</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Supervision" vocab-term-identifier="https://credit.niso.org/contributor-roles/supervision/">Supervision</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Project administration" vocab-term-identifier="https://credit.niso.org/contributor-roles/project-administration/">Project administration</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Funding acquisition" vocab-term-identifier="https://credit.niso.org/contributor-roles/funding-acquisition/">Funding acquisition</role><xref rid="af1-ijms-26-08618" ref-type="aff">1</xref><xref rid="c1-ijms-26-08618" ref-type="corresp">*</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-1188-8186</contrib-id><name name-style="western"><surname>Hofman</surname><given-names initials="B">Bart&#322;omiej</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Methodology" vocab-term-identifier="https://credit.niso.org/contributor-roles/methodology/">Methodology</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Validation" vocab-term-identifier="https://credit.niso.org/contributor-roles/validation/">Validation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Formal analysis" vocab-term-identifier="https://credit.niso.org/contributor-roles/formal-analysis/">Formal analysis</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/">Investigation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; review &amp; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#8211; review &amp; editing</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Visualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/visualization/">Visualization</role><xref rid="af2-ijms-26-08618" ref-type="aff">2</xref></contrib></contrib-group><contrib-group><contrib contrib-type="editor"><name name-style="western"><surname>Wiemer</surname><given-names initials="EAC">Erik A.C.</given-names></name><role>Academic Editor</role></contrib></contrib-group><aff id="af1-ijms-26-08618"><label>1</label>Department of Biochemistry and Molecular Biology, Centre of Postgraduate Medical Education, 01-813 Warsaw, Poland</aff><aff id="af2-ijms-26-08618"><label>2</label>Independent Researcher, 00-735 Warsaw, Poland; <email>hofman.bartlomiej@gmail.com</email></aff><author-notes><corresp id="c1-ijms-26-08618"><label>*</label>Correspondence: <email>k.rodzik@cmkp.edu.pl</email> or <email>gluchowskakm@gmail.com</email></corresp></author-notes><pub-date pub-type="epub"><day>04</day><month>9</month><year>2025</year></pub-date><pub-date pub-type="collection"><month>9</month><year>2025</year></pub-date><volume>26</volume><issue>17</issue><issue-id pub-id-type="pmc-issue-id">496188</issue-id><elocation-id>8618</elocation-id><history><date date-type="received"><day>08</day><month>8</month><year>2025</year></date><date date-type="rev-recd"><day>29</day><month>8</month><year>2025</year></date><date date-type="accepted"><day>31</day><month>8</month><year>2025</year></date></history><pub-history><event event-type="pmc-release"><date><day>04</day><month>09</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>13</day><month>09</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-09-13 11:25:14.803"><day>13</day><month>09</month><year>2025</year></date></event></pub-history><permissions><copyright-statement>&#169; 2025 by the authors.</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0/</ext-link>).</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="ijms-26-08618.pdf"/><abstract><p>Renal cancer is among the deadliest human malignancies. MCM7, a cell cycle-regulating protein, is frequently overexpressed in cancers and is associated with hyperproliferation and cancer progression. miR-25-3p, miR-93-5p, and miR-106b-5p form the miR-106b-25 cluster, located within the <italic toggle="yes">MCM7</italic> gene, and have previously been reported as upregulated in RCC. This study investigates whether miRNAs from the miR-106b-25 cluster regulate common target genes, enhance one another&#8217;s effect, and act synergistically with MCM7 to promote tumor progression. Tissue samples from clear cell RCC (ccRCC) and paired controls were analysed to assess MCM7 expression and genes targeted by the miR-106b-25 cluster. Findings were further validated using the TCGA-KIRC dataset. Functional studies in RCC-derived cell lines were conducted to evaluate the effects of miRNAs on target gene expression, as well as MCM7, and the combined contributions of MCM7 and the miR-106b-25 cluster to renal cancer progression. We demonstrate that MCM7 is upregulated at both transcript and protein levels in RCC, contributing to cancer progression by regulating cell proliferation and caspase-3/7 activity. Furthermore, we identified cancer-related genes aberrantly expressed in ccRCC (<italic toggle="yes">BRMS1L</italic>, <italic toggle="yes">CPEB3</italic>, <italic toggle="yes">DNAJB9</italic>, <italic toggle="yes">KIF3B</italic>, <italic toggle="yes">NFIB</italic>, <italic toggle="yes">PTPRJ</italic>, <italic toggle="yes">RBL2</italic>) and targeted by members of the miR-106b-25 cluster, suggesting that their dysregulation may be driven by these miRNAs. Inhibition of the miR-106b-25 cluster increases caspase-3/7 activity. These findings demonstrate that both MCM7 and the miR-106b-25 cluster contribute to renal cancer progression.</p></abstract><kwd-group><kwd>renal cancer</kwd><kwd><italic toggle="yes">MCM7</italic> gene</kwd><kwd>miR-106b-25 cluster</kwd><kwd>ccRCC (clear cell Renal Cell Carcinoma)</kwd><kwd>miR-25</kwd><kwd>miR-93</kwd><kwd>miR-106b</kwd><kwd><italic toggle="yes">BRMS1L</italic></kwd><kwd><italic toggle="yes">NFIB</italic></kwd><kwd>cancer progression</kwd></kwd-group><funding-group><award-group><funding-source>National Science Centre, Poland (Narodowe Centrum Nauki, NCN)</funding-source><award-id>2016/21/N/NZ5/00510</award-id><award-id>2018/28/T/NZ5/00467</award-id></award-group><funding-statement>This research was funded by the National Science Centre, Poland (Narodowe Centrum Nauki, NCN), grant numbers 2016/21/N/NZ5/00510 and 2018/28/T/NZ5/00467.</funding-statement></funding-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec sec-type="intro" id="sec1-ijms-26-08618"><title>1. Introduction</title><p>Kidney cancer accounts for approximately 2% of human cancers. In 2022 alone, over 434,000 new cases were diagnosed, and more than 155,000 deaths were attributed to the disease, making it the 16th leading cause of death in adults [<xref rid="B1-ijms-26-08618" ref-type="bibr">1</xref>]. Renal Cell Carcinoma (RCC) represents the most common type of kidney cancer, with clear cell Renal Cell Carcinoma (ccRCC, also known as conventional RCC) representing 75&#8211;80% of cases [<xref rid="B2-ijms-26-08618" ref-type="bibr">2</xref>,<xref rid="B3-ijms-26-08618" ref-type="bibr">3</xref>].</p><p>ccRCC is characterized by asymptomatic presentation, aggressive growth, and high metastatic potential. In total, 25% of patients present advanced, metastatic disease (mRCC) at first diagnosis, while another 30% develop a spread form of cancer following surgical intervention [<xref rid="B2-ijms-26-08618" ref-type="bibr">2</xref>,<xref rid="B3-ijms-26-08618" ref-type="bibr">3</xref>].</p><p>Although therapeutic strategies for mRCC have expanded in the past decade with the use of targeted therapy, immunotherapy, and personalized treatment, patients&#8217; survival remains poor. Similarly, improvement in understanding the genetic and molecular basis of RCC pathogenesis has revealed different possibilities in the field of biomarkers; none of them have been translated into clinical practice [<xref rid="B3-ijms-26-08618" ref-type="bibr">3</xref>,<xref rid="B4-ijms-26-08618" ref-type="bibr">4</xref>,<xref rid="B5-ijms-26-08618" ref-type="bibr">5</xref>]. More than 50% of mRCC patients die within 2 years of diagnosis, making kidney cancer a significant public health concern and major oncological challenge [<xref rid="B2-ijms-26-08618" ref-type="bibr">2</xref>]. Further studies elucidating the mechanism of cancer initiation and progression are critical to establishing not only early detection tools but also more effective targeted therapies&#8212;crucial factors for improving patient management and reducing mortality.</p><p>MCM7 protein (minichromosome maintenance complex component 7) belongs to the highly conserved MCMs family that forms the MCM2&#8211;7 complex. Upregulated in numerous human cancers, it promotes cell proliferation, invasion, and metastasis formation, which was confirmed in vitro and in vivo [<xref rid="B6-ijms-26-08618" ref-type="bibr">6</xref>,<xref rid="B7-ijms-26-08618" ref-type="bibr">7</xref>]. Elevated MCM7 expression negatively correlates with patient survival in hepatocellular and non-small cell lung cancer [<xref rid="B8-ijms-26-08618" ref-type="bibr">8</xref>,<xref rid="B9-ijms-26-08618" ref-type="bibr">9</xref>]. Consequently, MCM7 has been described as a tumor-associated gene and is considered a biomarker or even a therapeutic target [<xref rid="B10-ijms-26-08618" ref-type="bibr">10</xref>,<xref rid="B11-ijms-26-08618" ref-type="bibr">11</xref>,<xref rid="B12-ijms-26-08618" ref-type="bibr">12</xref>,<xref rid="B13-ijms-26-08618" ref-type="bibr">13</xref>,<xref rid="B14-ijms-26-08618" ref-type="bibr">14</xref>].</p><p>MCM7 serves as a &#8220;host gene&#8221; for the miR-106b-25 cluster (formed by three intronic microRNAs (miR-106b-5p, 93-5p, and 25-3p)), which is commonly described as &#8220;bi-oncogenic MCM7&#8211;miR-106b-25 component&#8221; [<xref rid="B15-ijms-26-08618" ref-type="bibr">15</xref>].</p><p>MicroRNAs (miRNAs, miRs) are short, non-coding ribonucleic acids (RNAs) that primarily function as regulators of target gene expression at the post-transcriptional level. While miRNAs expressed at a physiological level are essential for the development and maintenance of biological processes, their dysregulation has been associated with numerous human cancers. Over the past decades, the field of miRNA cancer research has expanded significantly, advancing understanding of their involvement in tumor biology on the one hand, but also providing their potential for diagnostic and therapeutic application in the clinic on the other [<xref rid="B16-ijms-26-08618" ref-type="bibr">16</xref>,<xref rid="B17-ijms-26-08618" ref-type="bibr">17</xref>,<xref rid="B18-ijms-26-08618" ref-type="bibr">18</xref>]. Similar to MCM7, overexpression of miR-25-3p, miR-93-5p, and miR-106b-5p has been demonstrated in many human cancers, including ccRCC. Their dysregulated levels have been described as one of the factors influencing tumor progression and clinical outcomes, supporting their potential as biomarkers [<xref rid="B19-ijms-26-08618" ref-type="bibr">19</xref>,<xref rid="B20-ijms-26-08618" ref-type="bibr">20</xref>,<xref rid="B21-ijms-26-08618" ref-type="bibr">21</xref>,<xref rid="B22-ijms-26-08618" ref-type="bibr">22</xref>].</p><p>The involvement of MCM7 in cancer progression and its potential as a diagnostic marker have been proven for human cancers [<xref rid="B13-ijms-26-08618" ref-type="bibr">13</xref>,<xref rid="B23-ijms-26-08618" ref-type="bibr">23</xref>]. However, MCM7&#8217;s role in RCC is rather limited and still needs a deeper understanding. Similarly, the results of elevated levels of miR-25-3p, miR-93-5p, and miR-106b-5p in ccRCC have been characterized for each individually; the whole cluster as an integrated unit has never been investigated in ccRCC. Moreover, the cooperative role of MCM7 and its hosted miR-106b-25 cluster in the progression of ccRCC is still unknown.</p><p>In this work, we aimed to explore the consequences of dysregulated levels of MCM7 and the hosted miR-106b-25 cluster on the progression of Renal Cell Carcinoma. We hypothesized that MCM7 levels in ccRCC are dysregulated and impact cancer progression. At the same time, we hypothesized that RNA molecules from the miR-106b-25 cluster commonly target the same dysregulated RCC progression-related genes, cooperate, and, as a unit with MCM7, are involved in ccRCC progression.</p></sec><sec sec-type="results" id="sec2-ijms-26-08618"><title>2. Results</title><sec sec-type="subjects" id="sec2dot1-ijms-26-08618"><title>2.1. MCM7 Is Significantly Upregulated in ccRCC Patients</title><p>First, to elucidate the expression of MCM7 in clear cell Renal Cell Carcinoma (ccRCC), we analyzed RNA and protein samples obtained from human ccRCC specimens. We observed upregulated <italic toggle="yes">MCM7</italic> transcript and protein levels in tumor samples compared to controls (<xref rid="ijms-26-08618-f001" ref-type="fig">Figure 1</xref>). The only group with no significant differences in <italic toggle="yes">MCM7</italic> mRNA levels was Group 2, which comprised TNM Stage III and IV specimens (N2, T2) (<xref rid="ijms-26-08618-f001" ref-type="fig">Figure 1</xref>). To our knowledge, this is the first study to report increased expression of MCM7 protein in patient-derived clear cell Renal Cell Carcinoma (ccRCC) specimens.</p><p>To further validate the observed alterations in MCM7 expression in clinical specimens, we analyzed data from the TCGA-KIRC cohort, which includes a large number of samples. Consistent with our findings, MCM7 was upregulated at both the transcript and protein levels across all analyzed groups, further corroborating our findings (<xref rid="ijms-26-08618-f002" ref-type="fig">Figure 2</xref>).</p></sec><sec id="sec2dot2-ijms-26-08618"><title>2.2. MCM7 Regulates Properties of Renal Cancer Cells</title><p>To study the consequences of upregulated levels of MCM7 in cancer progression, we silenced MCM7 expression in renal cancer cells, Caki-2 (<xref rid="ijms-26-08618-f0A1" ref-type="fig">Figure A1</xref>), and analyzed the effect on cell behavior. siRNA-mediated MCM7 knockdown significantly reduced proliferation and caspase-3/7 activity of RCC cells (<xref rid="ijms-26-08618-f003" ref-type="fig">Figure 3</xref>). Based on these results, we conclude that MCM7 acts as a tumor-associated gene in kidney cancer.</p></sec><sec id="sec2dot3-ijms-26-08618"><title>2.3. Targets of miR-106b-25 Cluster Are Abundantly Expressed in ccRCC</title><p>Our findings demonstrate that MCM7 is upregulated in clinical samples of ccRCC, and its inhibition reduces cellular proliferation and caspase-3/7 activity in RCC cells, confirming its oncogenic potential. MCM7 forms the MCM7&#8211;miR-106b-25 locus together with the miR-106b-25 cluster [<xref rid="B15-ijms-26-08618" ref-type="bibr">15</xref>]. miR-25-3p, miR-93-5p, and miR-106b-5p were previously studied in the same RCC specimens analyzed here, and all three, similar to MCM7, were found to be upregulated. Each miRNA, when studied individually, acts as &#8220;oncomiR&#8221; and triggers cancer progression [<xref rid="B20-ijms-26-08618" ref-type="bibr">20</xref>,<xref rid="B24-ijms-26-08618" ref-type="bibr">24</xref>]. However, little was known about their cooperative role in the regulation of common target genes in ccRCC, or the function of the MCM7&#8211;miR-106b-25 locus as a four-component unit acting simultaneously.</p><p>To identify common targets regulated by all three microRNAs from the miR-106b-25 cluster, we employed a comprehensive approach incorporating multiple web-based tools: miRDB, mirDIP, miRSystem, and TargetScan. This analysis identified 92 potential targets (<xref rid="ijms-26-08618-t0A4" ref-type="table">Table A4</xref> in <xref rid="app1-ijms-26-08618" ref-type="app">Appendix A</xref>). From these, we prioritized genes that: (i) have been implicated in biological processes investigated in this study, (ii) were predicted by at least three algorithms, and (iii) contain miRNA-binding sites within their 3&#8242;UTRs as identified by TargetScan. In total, 12 genes&#8211;<italic toggle="yes">ATXN1</italic>, <italic toggle="yes">BRMS1L</italic>, <italic toggle="yes">CPEB3</italic>, <italic toggle="yes">COL14A1</italic>, <italic toggle="yes">DNAJB9</italic>, <italic toggle="yes">DOCK4</italic>, <italic toggle="yes">KIF3B</italic>, <italic toggle="yes">NEDD4L</italic>, <italic toggle="yes">NFIB, PTPRJ</italic>, <italic toggle="yes">RBL2</italic>, and <italic toggle="yes">SMAD7</italic>&#8212;were selected for further analysis.</p><p>The expression of selected genes was measured by qPCR in the same tissue samples used for MCM7 analysis in this study, as well as previously for members of the miR-106b-25 cluster [<xref rid="B20-ijms-26-08618" ref-type="bibr">20</xref>,<xref rid="B24-ijms-26-08618" ref-type="bibr">24</xref>]. Considerable changes in expression were observed for 7 out of 12 studied genes. <italic toggle="yes">BRMS1L</italic>, <italic toggle="yes">CPEB3</italic>, <italic toggle="yes">KIF3B</italic>, and <italic toggle="yes">NEDD4L</italic> showed decreased mRNA expression in both low (N1/T1&#8212;Group 1) and high (N2/T2&#8212;Group 2) stage tumors. <italic toggle="yes">PTPRJ</italic> and <italic toggle="yes">RBL2</italic> were downregulated exclusively in high-stage tumors (N2/T2&#8212;Group 2). For all of the aforementioned genes, a significant reduction in mRNA levels was observed when all specimens were analyzed collectively. In contrast, <italic toggle="yes">SMAD7</italic> expression was significantly increased in tissue specimens from patients with TNM Stage I and II (Group 1) (<xref rid="ijms-26-08618-f004" ref-type="fig">Figure 4</xref>). No significant changes were observed for <italic toggle="yes">ATXN1</italic>, <italic toggle="yes">DNAJB9</italic>, and <italic toggle="yes">NFIB</italic>; the expression of <italic toggle="yes">COL14A1</italic> and <italic toggle="yes">DOCK4</italic> was below the detection threshold.</p><p>To validate our findings on the expression of ccRCC-progression-related genes in clinical specimens, we analyzed data from a large clinical cohort of KIRC samples in the TCGA database. <italic toggle="yes">ATXN1</italic>, <italic toggle="yes">DNAJB9</italic>, and <italic toggle="yes">NFIB</italic> exhibited increased expression levels in both low- and high-TNM-stage KIRC, as well as in the combined analysis of all samples. <italic toggle="yes">BRMS1L</italic>, <italic toggle="yes">CPEB3</italic>, <italic toggle="yes">KIF3B</italic>, <italic toggle="yes">NEDD4L</italic>, <italic toggle="yes">PTPRJ</italic>, and <italic toggle="yes">RBL2</italic> were significantly downregulated in tumor samples compared to controls. <italic toggle="yes">SMAD7</italic> expression tended to be downregulated across all analyzed sample groups; however, these changes were not statistically significant (<xref rid="ijms-26-08618-f005" ref-type="fig">Figure 5</xref>).</p></sec><sec id="sec2dot4-ijms-26-08618"><title>2.4. microRNAs from the miR-106b-25 Cluster Regulate the Expression of ccRCC-Progression-Related Genes by Directly Targeting Their 3&#8242;UTRs</title><p>To determine if observed changes in identified genes resulted from altered microRNA activity, we transfected two RCC-derived cell lines&#8212;Caki-2 and KIJ-265T&#8212;with synthetic miRNA mimics. The effect of elevated levels of each miRNA, as well as all three working simultaneously as a &#8220;miRNA cluster,&#8221; on the studied genes was measured using the qPCR method. In Caki-2 cells, all three microRNAs (miR-25-3p, miR-93-5p, and miR-106b-5p) suppressed expression of <italic toggle="yes">BRMS1L</italic> and <italic toggle="yes">NFIB</italic>. Additionally, miR-25-3p inhibited expression of <italic toggle="yes">DNAJB9</italic>, <italic toggle="yes">KIF3B</italic>, <italic toggle="yes">NEDD4L</italic>, and <italic toggle="yes">PTPRJ</italic>; miR-93-5p downregulated <italic toggle="yes">ATXN1, KIF3B,</italic> and <italic toggle="yes">RBL2</italic>. In a second RCC model&#8212;KIJ-265T cells, all three microRNAs negatively regulated <italic toggle="yes">BRMS1L</italic>. Furthermore, miR-25-3p inhibited <italic toggle="yes">CPEB3</italic>, <italic toggle="yes">DNAJB9</italic>, <italic toggle="yes">KIF3B</italic>, <italic toggle="yes">NFIB</italic>, <italic toggle="yes">PTPRJ</italic>, and <italic toggle="yes">SMAD7</italic>; miR-93-5p reduced expression of <italic toggle="yes">RBL2</italic> and slightly enhanced <italic toggle="yes">SMAD7</italic> levels; miR-106b-5p downregulated <italic toggle="yes">RBL2</italic>. Simultaneous co-transfection of cells with all three miRNAs from the miR-106b-25 cluster did not enhance the repressive effect observed with individual miRNAs (<xref rid="ijms-26-08618-f006" ref-type="fig">Figure 6</xref>).</p><p>To further validate the regulatory activity of miRNAs on the studied genes, a luciferase assay was performed. We focused on genes regulated simultaneously by all three microRNAs (<italic toggle="yes">BRMS1L</italic>, <italic toggle="yes">NFIB</italic>), and those exhibiting expression changes exceeding 20% following miRNA overexpression with miRNA mimics (<italic toggle="yes">CPEB3</italic>, <italic toggle="yes">DNAJB9</italic>, <italic toggle="yes">KIF3B</italic>, <italic toggle="yes">PTPRJ</italic>, <italic toggle="yes">RBL2</italic>). Using TargetScan, we identified binding sites in their 3&#8242;UTRs with the miRNA-response elements (MREs) and introduced them downstream of the luciferase reporter gene in the pmirGLO vector. Co-transfection of corresponding constructs with miRNA mimics (miR-25-3p, miR-93-5p, or miR-106b-5p) into RCC cells caused a significant inhibition of luciferase activity for all genes chosen for analysis (<xref rid="ijms-26-08618-f007" ref-type="fig">Figure 7</xref>A&#8211;G). No changes were observed after co-transfection of mimics with the control pmirGLO plasmid lacking the MREs (<xref rid="ijms-26-08618-f007" ref-type="fig">Figure 7</xref>H).</p><p>Collectively, these data indicate that each of the studied genes (<italic toggle="yes">BRMS1L</italic>, <italic toggle="yes">CPEB3</italic>, <italic toggle="yes">DNAJB9</italic>, <italic toggle="yes">KIF3B</italic>, <italic toggle="yes">NFIB</italic>, <italic toggle="yes">PTPRJ</italic>, and <italic toggle="yes">RBL2</italic>) is regulated by at least one of the miRNAs from the miR-106b-25 cluster, and <italic toggle="yes">BRMS1L</italic> and <italic toggle="yes">NFIB</italic> are simultaneously targeted by all three microRNAs. However, no enhanced regulatory effect is observed when all three miRNAs act simultaneously.</p></sec><sec id="sec2dot5-ijms-26-08618"><title>2.5. Components of the MCM7-miR-106b-25 Locus Affect Properties of RCC Cells</title><p>The amplification of the <italic toggle="yes">MCM7&#8211;miR-106b-25</italic> locus was reported in human cancers. Studies have shown that each factor derived from the locus exerts mainly oncogenic properties and contributes to cancer progression [<xref rid="B6-ijms-26-08618" ref-type="bibr">6</xref>,<xref rid="B7-ijms-26-08618" ref-type="bibr">7</xref>,<xref rid="B13-ijms-26-08618" ref-type="bibr">13</xref>,<xref rid="B21-ijms-26-08618" ref-type="bibr">21</xref>,<xref rid="B22-ijms-26-08618" ref-type="bibr">22</xref>,<xref rid="B25-ijms-26-08618" ref-type="bibr">25</xref>,<xref rid="B26-ijms-26-08618" ref-type="bibr">26</xref>,<xref rid="B27-ijms-26-08618" ref-type="bibr">27</xref>,<xref rid="B28-ijms-26-08618" ref-type="bibr">28</xref>,<xref rid="B29-ijms-26-08618" ref-type="bibr">29</xref>].</p><p>However, the expression and role of MCM7 in ccRCC progression remain rather poorly described. The individual roles of miR-25-3p, miR-93-5p, and miR-106b-5p in ccRCC have been previously characterized [<xref rid="B20-ijms-26-08618" ref-type="bibr">20</xref>,<xref rid="B24-ijms-26-08618" ref-type="bibr">24</xref>,<xref rid="B30-ijms-26-08618" ref-type="bibr">30</xref>,<xref rid="B31-ijms-26-08618" ref-type="bibr">31</xref>]; the concomitant action of the three microRNAs acting as a single functional factor, as well as the combined role of MCM7 and the miR-106b-25 cluster as a whole, has not been described. Given the fact that all factors from the MCM7-miR-106b-25 locus are overexpressed in ccRCC, we set out to evaluate if they cooperate in processes associated with renal cancer progression.</p><p>Two previously adapted cell line models&#8211;Caki-2 and KIJ-265T&#8211;were co-transfected with siRNA targeting MCM7 and miRNA inhibitors to silence MCM7 alone, miR-106b-25 alone, or both MCM7 and miR-106b-25 simultaneously (<xref rid="ijms-26-08618-f0A2" ref-type="fig">Figure A2</xref>). The functional effect of these changes on RCC cells&#8217; properties was evaluated using the BrdU assay for cellular proliferation and the caspase-3/7 activity assay.</p><p>Consistent with previous results (<xref rid="ijms-26-08618-f003" ref-type="fig">Figure 3</xref>), reduced MCM7 expression inhibited the proliferation of both Caki-2 and KIJ-265T cells. Although combined inhibition of MCM7 and miR-106b-25 cluster significantly decreased Caki-2 cells&#8217; proliferation, we attribute this effect to MCM7 knockdown, as the inhibition of the miR-106b-25 cluster alone had no impact on proliferation in any RCC cell line used (<xref rid="ijms-26-08618-f008" ref-type="fig">Figure 8</xref>A).</p><p>Similarly, reduced MCM7 expression decreased caspase-3/7 activity in both Caki-2 and KIJ-265T cells. In contrast, inhibition of the miR-106b-25 cluster significantly enhanced caspase-3/7 activity in KIJ-265T cells, while a similar trend was observed in Caki-2 cells. Simultaneous reduction in both MCM7 and miR-106b-25 activity showed no effect on caspase-3/7 activity, probably because the individual effects of each factor were abandoned (<xref rid="ijms-26-08618-f008" ref-type="fig">Figure 8</xref>B).</p></sec></sec><sec sec-type="discussion" id="sec3-ijms-26-08618"><title>3. Discussion</title><p>In this study, we demonstrate that MCM7 expression is upregulated in renal cancer and affects cell proliferation and caspase-3/7 activity, contributing to RCC progression. miR-106b-25 cluster contributes to the expression of several key genes, including transcription factors&#8211;BRMS1L [<xref rid="B32-ijms-26-08618" ref-type="bibr">32</xref>], NFIB [<xref rid="B33-ijms-26-08618" ref-type="bibr">33</xref>]; translation and protein stability regulators&#8211;CPEB3 [<xref rid="B34-ijms-26-08618" ref-type="bibr">34</xref>], DNAJB9 [<xref rid="B35-ijms-26-08618" ref-type="bibr">35</xref>]; proto-oncogene&#8211;KIF3B [<xref rid="B36-ijms-26-08618" ref-type="bibr">36</xref>], and cell signaling molecule&#8211;PTPRJ [<xref rid="B37-ijms-26-08618" ref-type="bibr">37</xref>]. Most of these genes have been described as tumor suppressors regulating cancer progression. We demonstrate that the expression of these genes is dysregulated in RCC clinical specimens, supporting their potential contribution to the development and progression of RCC. In RCC cells, seven genes (<italic toggle="yes">BRMS1L</italic>, <italic toggle="yes">CPEB3</italic>, <italic toggle="yes">DNAJB9</italic>, <italic toggle="yes">KIF3B</italic>, <italic toggle="yes">NFIB</italic>, <italic toggle="yes">PTPRJ</italic>, <italic toggle="yes">RBL2</italic>) are directly regulated by at least one miRNA from the miR-106b-25 cluster, and two genes&#8211;<italic toggle="yes">BRMS1L</italic> and <italic toggle="yes">NFIB</italic>&#8211;are simultaneously targeted by all three studied microRNAs. Among the studied microRNAs, miR-25-3p emerges as the most potent regulator, targeting six of the analyzed genes (<italic toggle="yes">BRMS1L</italic>, <italic toggle="yes">CPEB3</italic>, <italic toggle="yes">DNAJB9</italic>, <italic toggle="yes">KIF3B</italic>, <italic toggle="yes">NFIB</italic>, <italic toggle="yes">PTPRJ</italic>). Functional assays demonstrated that MCM7 regulates both proliferation and caspase-3/7 activity in RCC cells, whereas the miR-106b-25 cluster affects caspase-3/7 activity.</p><p>MCM7&#8211;miR-106b-25 complex consists of MCM7 &#8220;host gene&#8221; and three intronic microRNAs (miR-106b-5p, 93-5p, and 25-3p), localized on the 7q22 locus frequently amplified in human cancers, including ccRCC [<xref rid="B38-ijms-26-08618" ref-type="bibr">38</xref>,<xref rid="B39-ijms-26-08618" ref-type="bibr">39</xref>,<xref rid="B40-ijms-26-08618" ref-type="bibr">40</xref>]. MCM7 protein is part of the highly conserved MCMs family, which forms the MCM2&#8211;7 complex&#8211;a key regulator of DNA replication and genome stability. MCM7 is expressed at low levels in normal tissue, but is frequently upregulated in human cancers [<xref rid="B28-ijms-26-08618" ref-type="bibr">28</xref>,<xref rid="B41-ijms-26-08618" ref-type="bibr">41</xref>,<xref rid="B42-ijms-26-08618" ref-type="bibr">42</xref>,<xref rid="B43-ijms-26-08618" ref-type="bibr">43</xref>]. High MCM7 expression was correlated with shorter overall survival in several cancers, including hepatocellular carcinoma [<xref rid="B8-ijms-26-08618" ref-type="bibr">8</xref>], esophageal squamous cell carcinoma [<xref rid="B44-ijms-26-08618" ref-type="bibr">44</xref>], and liver cancer [<xref rid="B45-ijms-26-08618" ref-type="bibr">45</xref>], highlighting its potential as a prognostic and predictive biomarker. In pancreatic ductal adenocarcinoma (PDAC) [<xref rid="B46-ijms-26-08618" ref-type="bibr">46</xref>], liver [<xref rid="B45-ijms-26-08618" ref-type="bibr">45</xref>], breast [<xref rid="B47-ijms-26-08618" ref-type="bibr">47</xref>], and colon cancers [<xref rid="B46-ijms-26-08618" ref-type="bibr">46</xref>], MCM7 was shown to influence therapeutic response, supporting its promise as a potential therapeutic target.</p><p>The role of MCM7 in RCC is not yet fully elucidated. Although <italic toggle="yes">MCM7</italic> expression in ccRCC has been documented using high-throughput approaches [<xref rid="B38-ijms-26-08618" ref-type="bibr">38</xref>,<xref rid="B48-ijms-26-08618" ref-type="bibr">48</xref>], transcriptional profiling of <italic toggle="yes">MCM7</italic> in ccRCC patients is limited to studies by Liu et al. [<xref rid="B49-ijms-26-08618" ref-type="bibr">49</xref>] and Zhang et al. [<xref rid="B50-ijms-26-08618" ref-type="bibr">50</xref>], highlighting the need for further validation and assessment at the protein level. Here, we demonstrate that <italic toggle="yes">MCM7</italic> is upregulated at the transcriptional level in ccRCC samples, corroborating previous findings reported by Liu et al. [<xref rid="B49-ijms-26-08618" ref-type="bibr">49</xref>] and Zhang et al. [<xref rid="B50-ijms-26-08618" ref-type="bibr">50</xref>], and that its protein expression is also elevated in tumor tissue, implicating its role in RCC progression. To our knowledge, this is the first report showing dysregulation of MCM7 at the protein level in ccRCC, as earlier evidence, although consistent with our observations, was limited to immunohistochemical analysis from the Human Protein Atlas [<xref rid="B51-ijms-26-08618" ref-type="bibr">51</xref>].</p><p>Elevated expression of MCM7 enhances DNA synthesis, promotes cell proliferation, invasion, and contributes to overall cancer progression [<xref rid="B7-ijms-26-08618" ref-type="bibr">7</xref>,<xref rid="B41-ijms-26-08618" ref-type="bibr">41</xref>,<xref rid="B44-ijms-26-08618" ref-type="bibr">44</xref>,<xref rid="B45-ijms-26-08618" ref-type="bibr">45</xref>]. To evaluate the functional relevance of the observed MCM7 upregulation in RCC, we knocked down its expression in Caki-2 and KIJ-265T RCC cells, which significantly reduced proliferation and caspase-3/7 activity. These findings align with previous observations in RCC cell lines 786-O and A-498 [<xref rid="B50-ijms-26-08618" ref-type="bibr">50</xref>], as well as in hepatocellular carcinoma [<xref rid="B6-ijms-26-08618" ref-type="bibr">6</xref>], and esophageal squamous cell carcinoma [<xref rid="B44-ijms-26-08618" ref-type="bibr">44</xref>], where MCM7 inhibition similarly suppressed cell proliferation. Most importantly, they confirm the role of MCM7 as a regulator of RCC progression.</p><p>Polycistronic microRNAs are often co-dysregulated through shared regulatory mechanisms [<xref rid="B52-ijms-26-08618" ref-type="bibr">52</xref>]. Several studies have shown that individual members of the miR-106b-25 cluster are upregulated in ccRCC. When examined separately, each microRNA functions as an &#8220;oncomiR&#8221;, promoting cancer progression by regulating an individual set of target genes [<xref rid="B20-ijms-26-08618" ref-type="bibr">20</xref>,<xref rid="B24-ijms-26-08618" ref-type="bibr">24</xref>,<xref rid="B30-ijms-26-08618" ref-type="bibr">30</xref>,<xref rid="B53-ijms-26-08618" ref-type="bibr">53</xref>,<xref rid="B54-ijms-26-08618" ref-type="bibr">54</xref>,<xref rid="B55-ijms-26-08618" ref-type="bibr">55</xref>,<xref rid="B56-ijms-26-08618" ref-type="bibr">56</xref>,<xref rid="B57-ijms-26-08618" ref-type="bibr">57</xref>]. This suggests that in RCC, all three may be dysregulated by a common mechanism and act cooperatively to regulate shared target genes, reinforcing each other&#8217;s effect. All three microRNAs were upregulated and repressed NEDD4L [<xref rid="B21-ijms-26-08618" ref-type="bibr">21</xref>], EP300 [<xref rid="B58-ijms-26-08618" ref-type="bibr">58</xref>], and SMAD7 [<xref rid="B59-ijms-26-08618" ref-type="bibr">59</xref>] in breast cancer, influencing epithelial&#8211;mesenchymal transition, tumoral transformation, and therapy response. In non-small cell lung cancer, miR-106b-25 cluster targets b-TRCP2 and enhances cell migration and invasion [<xref rid="B60-ijms-26-08618" ref-type="bibr">60</xref>], while in acute myeloid leukemia (AML), it targets CASP7, influencing cell proliferation, chemoresistance, and apoptosis [<xref rid="B61-ijms-26-08618" ref-type="bibr">61</xref>]. Elevated expression of the entire cluster in chronic lymphocytic leukemia (CLL) [<xref rid="B22-ijms-26-08618" ref-type="bibr">22</xref>] and lung cancer [<xref rid="B62-ijms-26-08618" ref-type="bibr">62</xref>] further supports their coordinated role.</p><p>Using miRNA target prediction tools, we identified 12 genes commonly targeted by all three microRNAs of the miR-106b-25 cluster. Given that MCM7 is primarily involved in cell proliferation&#8211;and miRNA from this cluster are also known to regulate this process&#8211;we focused on genes related mainly, though not exclusively, to proliferation. The expression levels of <italic toggle="yes">ATXN1</italic>, <italic toggle="yes">BRMS1L</italic>, <italic toggle="yes">COL14A1</italic>, <italic toggle="yes">CPEB3</italic>, <italic toggle="yes">DNAJB9</italic>, <italic toggle="yes">DOCK4</italic>, <italic toggle="yes">KIF3B</italic>, <italic toggle="yes">NEDD4L</italic>, <italic toggle="yes">NFIB</italic>, <italic toggle="yes">PTPRJ</italic>, <italic toggle="yes">RBL2</italic>, <italic toggle="yes">SMAD7</italic> were evaluated in the same ccRCC specimen as MCM7. Among these, six genes&#8211;<italic toggle="yes">BRMS1L</italic>, <italic toggle="yes">CPEB3</italic>, <italic toggle="yes">KIF3B</italic>, <italic toggle="yes">NEDD4L</italic>, <italic toggle="yes">PTPRJ</italic>, and <italic toggle="yes">RBL2</italic>&#8211;showed significantly decreased expression, while <italic toggle="yes">SMAD7</italic> was significantly upregulated in low-stage tumors. These observations were further supported by KIRC-TCGA data, which confirmed decreased expression of <italic toggle="yes">BRMS1L</italic>, <italic toggle="yes">CPEB3</italic>, <italic toggle="yes">KIF3B</italic>, <italic toggle="yes">NEDD4L</italic>, <italic toggle="yes">PTPRJ</italic>, and <italic toggle="yes">RBL2</italic>.</p><p>Given that all three miR-106b-25 members were previously found to be upregulated in the same samples analyzed here [<xref rid="B20-ijms-26-08618" ref-type="bibr">20</xref>,<xref rid="B24-ijms-26-08618" ref-type="bibr">24</xref>], the observed dysregulation of their potential targets suggests these miRNAs&#8217; role in altered gene expression. In RCC-derived cell lines Caki-2 and KIJ-265T, we demonstrated downregulation of <italic toggle="yes">BRMS1L</italic>, <italic toggle="yes">CPEB3</italic>, <italic toggle="yes">DNAJB9</italic>, <italic toggle="yes">KIF3B</italic>, <italic toggle="yes">NFIB</italic>, <italic toggle="yes">PTPRJ</italic>, and <italic toggle="yes">RBL2</italic> following overexpression of individual microRNA. Specifically, miR-25-3p reduced transcript levels of <italic toggle="yes">BRMS1L</italic>, <italic toggle="yes">CPEB3</italic>, <italic toggle="yes">DNAJB9</italic>, <italic toggle="yes">KIF3B</italic>, <italic toggle="yes">NFIB</italic>, and <italic toggle="yes">PTPRJ</italic>; miR-93-5p suppressed <italic toggle="yes">BRMS1L</italic>, <italic toggle="yes">KIF3B</italic>, and <italic toggle="yes">NFIB</italic>; and miR-106b-5p affected <italic toggle="yes">BRMS1L</italic>, <italic toggle="yes">NFIB</italic>, and <italic toggle="yes">RBL2</italic>. Our studies identify <italic toggle="yes">BRMS1L</italic> and <italic toggle="yes">NFIB</italic> as novel shared targets of all three microRNAs. Among them, miR-25-3p emerges as the most potent regulator, targeting six of the analyzed genes.</p><p>Notably, overexpression of each miRNA individually caused reduced expression of <italic toggle="yes">BRMS1L</italic> and <italic toggle="yes">NFIB</italic>; however, simultaneous co-expression of all three miRNAs did not provide an additive or synergistic effect compared to individual miRNAs.</p><p>Two&#8211;miR-106b-5p and miR-93-5p&#8211; microRNAs share the same seed sequence, which supports their ability to regulate common transcripts. miR-25-3p has a distinct seed sequence&#8212;implying it targets a different region of the 3&#8242;UTR and potentially enhances the miR-93/106b activity [<xref rid="B63-ijms-26-08618" ref-type="bibr">63</xref>]. The lack of observable additive or synergistic effects may stem from multiple mechanisms. Beyond target site accessibility and miRNA binding affinity, factors such as mRNA structure and its changes, and competing RNAs can influence miRNA&#8211;mRNA interactions and shape the regulatory potential of clustered miRNAs [<xref rid="B64-ijms-26-08618" ref-type="bibr">64</xref>,<xref rid="B65-ijms-26-08618" ref-type="bibr">65</xref>]. Moreover, a single microRNA can regulate multiple transcripts, while a single transcript may contain binding sites for several microRNAs. This suggests that, at least for miR-93 and miR-106b, concurrent overexpression may lead to competition for binding to shared targets, a phenomenon known as &#8220;competitive interaction&#8221; [<xref rid="B64-ijms-26-08618" ref-type="bibr">64</xref>]. Additionally, miRNAs may also fulfill a redundant role in buffering transcriptomic balance, a function particularly relevant for co-expressed microRNAs that act within the same pathways or biological processes [<xref rid="B66-ijms-26-08618" ref-type="bibr">66</xref>].</p><p>To fully elucidate the interplay among these miRNAs, further studies addressing the aforementioned mechanisms are required.</p><p>BRMS1L (breast cancer metastasis suppressor 1-like) is a transcription factor with tumor-suppressive functions reported in breast [<xref rid="B67-ijms-26-08618" ref-type="bibr">67</xref>,<xref rid="B68-ijms-26-08618" ref-type="bibr">68</xref>], ovarian [<xref rid="B69-ijms-26-08618" ref-type="bibr">69</xref>], and non-small cell lung cancer [<xref rid="B32-ijms-26-08618" ref-type="bibr">32</xref>], where it inhibits migration and invasion, thereby limiting metastasis. Its downregulation is associated with metastasis and poor survival in breast [<xref rid="B68-ijms-26-08618" ref-type="bibr">68</xref>], ovarian [<xref rid="B69-ijms-26-08618" ref-type="bibr">69</xref>], and brain cancers [<xref rid="B70-ijms-26-08618" ref-type="bibr">70</xref>], supporting its role as a prognostic biomarker and therapeutic target. To our knowledge, to date, BRMS1L has not been studied in kidney cancer. Based on its function in other malignancies, we hypothesized that BRMS1L may have similar relevance in RCC and serve as a biomarker, and its restoration could offer therapeutic benefits in kidney cancer. This also supports the evidence for the oncogenic potential of miR-106b-25 cluster, which negatively regulates <italic toggle="yes">BRMS1L</italic> expression.</p><p>NFIB is a member of the nuclear factor I (NFI) family of transcription factors, with a cancer-specific role [<xref rid="B71-ijms-26-08618" ref-type="bibr">71</xref>]. In gastric [<xref rid="B72-ijms-26-08618" ref-type="bibr">72</xref>] and colorectal cancer [<xref rid="B73-ijms-26-08618" ref-type="bibr">73</xref>], it promotes proliferation, invasion, and metastasis. In contrast, in oral cancer [<xref rid="B74-ijms-26-08618" ref-type="bibr">74</xref>] and glioblastoma [<xref rid="B75-ijms-26-08618" ref-type="bibr">75</xref>], NFIB acts as a tumor suppressor. In kidney cancer, Wang et al. (2021) [<xref rid="B76-ijms-26-08618" ref-type="bibr">76</xref>] reported that NFIB regulates PTEN-induced kinase 1 (PINK1), promoting proliferation, migration, and metastasis formation of RCC. High NFIB expression is associated with poor tumor grade, metastasis, and worse patient prognosis [<xref rid="B76-ijms-26-08618" ref-type="bibr">76</xref>]. These findings suggest that NFIB plays an oncogenic role in RCC, and its regulation by the miR-106b-25 cluster, as shown in our study, may have important therapeutic implications.</p><p>Studies by Poliseno et al. [<xref rid="B15-ijms-26-08618" ref-type="bibr">15</xref>] demonstrated that in prostate cancer, although MCM7 plays a crucial role in tumorigenesis, the simultaneous overexpression and cooperation of the miR-106b-25 cluster is required for oncogenicity. In this study, we show for the first time that the MCM7 protein is upregulated in RCC and confirm its role in cancer proliferation. In contrast to previous reports where individual miRNAs of the cluster promoted renal cancer cell proliferation [<xref rid="B20-ijms-26-08618" ref-type="bibr">20</xref>,<xref rid="B24-ijms-26-08618" ref-type="bibr">24</xref>,<xref rid="B54-ijms-26-08618" ref-type="bibr">54</xref>,<xref rid="B77-ijms-26-08618" ref-type="bibr">77</xref>,<xref rid="B78-ijms-26-08618" ref-type="bibr">78</xref>,<xref rid="B79-ijms-26-08618" ref-type="bibr">79</xref>], concomitant inhibition of the three miRNAs did not change ccRCC proliferation. We observed that MCM7 silencing attenuated the caspase-3/7 activity in both renal cancer cell models&#8211;Caki-2 and KIJ-265T. In contrast, simultaneous inhibition of the three miRNAs resulted in upregulation of caspase-3/7 activity. Interestingly, in glioma cells, MCM7 silencing increases caspase 3/7 activity, as reported by Erkan et al. [<xref rid="B80-ijms-26-08618" ref-type="bibr">80</xref>]. In alignment with our findings, Hu et al. demonstrated that overexpression of the miR-106b-25 cluster in minimally transformed mammary epithelial cells (MTMECs) suppresses caspase-9 and caspase-3/7 activity [<xref rid="B58-ijms-26-08618" ref-type="bibr">58</xref>]. As mentioned previously, in AML, miR-106b-25 targets CASP7 [<xref rid="B61-ijms-26-08618" ref-type="bibr">61</xref>]. Further studies are needed to elucidate the functional impact of the altered expression of the MCM7-miR-106b-25 axis in renal cancer.</p><p>In conclusion, our study demonstrates that MCM7 mRNA and protein levels are upregulated in renal cancer. The microRNAs&#8211;miR-25-3p, 93-5p, and 106b-5p&#8211;encoded within the <italic toggle="yes">MCM7</italic> gene&#8211;regulate genes that are dysregulated in RCC. Based on our findings, we conclude that elevated MCM7 and miR-106b-25 expression contribute to renal cancer progression.</p><p>Despite these benefits, the studies described here have some limitations. As reported, microRNAs operate within complex regulatory networks, often acting redundantly across multiple pathways. Furthermore, cellular pathways are to some degree interrelated, just as one miRNA to another [<xref rid="B66-ijms-26-08618" ref-type="bibr">66</xref>]. In our approach, we focus on the regulatory role of a single member or the combined effect of all three members of the miR-106b-25 cluster, with an emphasis specifically on cellular proliferation. While we identified over 90 genes as shared targets of all three miRNAs, each miRNA has hundreds of additional targets not explored here. Likewise, other pathways regulated by the miR-106b-25 cluster may also influence miRNA function and cellular proliferation; however, they were beyond the scope of this study. Further research exploring the interrelations between individual cluster members is needed to comprehensively understand their roles.</p><p>Our study provides novel insight into the molecular mechanisms driving RCC progression and highlights potential directions for translational research, which is particularly important given the lack of reliable biomarkers and limited treatment options for advanced RCC [<xref rid="B81-ijms-26-08618" ref-type="bibr">81</xref>].</p><p>In our study, we observed upregulation of MCM7 protein in RCC tissues compared to matched controls. Taking into account previous reports that identify MCM7 as a sensitive diagnostic marker [<xref rid="B10-ijms-26-08618" ref-type="bibr">10</xref>,<xref rid="B82-ijms-26-08618" ref-type="bibr">82</xref>], further studies can elucidate its clinical utility in RCC, including its role in shaping therapeutic response [<xref rid="B45-ijms-26-08618" ref-type="bibr">45</xref>]. Similarly, the upregulated miRNAs from the miR-106b-25 cluster have previously been reported as potential diagnostic biomarkers, with expression levels correlating with patient outcomes [<xref rid="B20-ijms-26-08618" ref-type="bibr">20</xref>,<xref rid="B24-ijms-26-08618" ref-type="bibr">24</xref>,<xref rid="B79-ijms-26-08618" ref-type="bibr">79</xref>]. In this study, we identified a subset of cancer-related genes regulated by members of this cluster, indicative of a microRNA-mRNA interaction network, and providing novel opportunities for the development of diagnostic biomarkers.</p><p>Collectively, our findings broaden knowledge about molecular changes driving RCC progression, supporting its relevance as a candidate for future diagnostic and therapeutic strategies in RCC.</p></sec><sec id="sec4-ijms-26-08618"><title>4. Materials and Methods</title><sec id="sec4dot1-ijms-26-08618"><title>4.1. Tissue Specimens</title><p>Twenty matched pairs of ccRCC (T) and non-cancerous-adjacent (N) tissue (for protein isolation), along with RNA isolated from 56 matched pairs, were retrieved from The Local Tissue Bank at The Department of Biochemistry and Molecular Biology, Centre of Postgraduate Medical Education. Collection and sample use were authorized by the Institutional Bioethics Committee of the Centre of Postgraduate Medical Education (No. 18/PB/2012, 75/PB-A/2014, 47/PB/2017). Written informed consent was signed by all patients.</p></sec><sec id="sec4dot2-ijms-26-08618"><title>4.2. Cell Lines Culture</title><p>The Caki-2 (HTB-47<sup>&#8482;</sup>) RCC-derived cell line was purchased from ATCC (Manassas, VA, USA) and maintained according to the provider&#8217;s instructions (McCoy&#8217;s 5A Medium Modified (Sigma Aldrich, St. Louis, MO, USA) supplemented with heat-inactivated Fetal Bovine Serum (Sigma Aldrich) to a final concentration of 10% and penicillin/streptomycin (Sigma Aldrich) to a final concentration of 1%). The KIJ-265T cell line was kindly provided by J.A. Copland (Mayo Foundation for Medical Education and Research, Rochester, MN, USA) and maintained in Minimal Essential Medium (MEM, Sigma Aldrich) containing 10% heat-inactivated Fetal Bovin Serum, 1% MEM Non-Essential Amino Acid Solution (MEM NEAA, Sigma Aldrich), 1% sodium pyruvate (Sigma Aldrich) and 1% penicillin/streptomycin (Sigma Aldrich).</p></sec><sec id="sec4dot3-ijms-26-08618"><title>4.3. Transient Transfections with siRNA and Mimics</title><p>All transfections were performed using Lipofectamine<sup>TM</sup> 2000 reagent (Invitrogen, Carlsbad, CA, USA) according to the manufacturer&#8217;s protocol. Cells were seeded in complete medium on 6-well, 12-well, or 96-well plates. The following day, cells were transfected with miRCURY LNA microRNA mimics, inhibitors, or control oligonucleotides (Qiagen, Germantown, MD, USA), anti-MCM7 siRNA, Silencer Select Negative Control No. 1 (<xref rid="ijms-26-08618-t0A1" ref-type="table">Table A1</xref> in <xref rid="app1-ijms-26-08618" ref-type="app">Appendix A</xref>), or a combination of miRCURY LNA microRNA inhibitors and small interfering RNA (as described in the graphs below). Cultured cells were incubated for 48 h or 72 h and then collected for further post-transfection analysis.</p></sec><sec id="sec4dot4-ijms-26-08618"><title>4.4. Gene Expression Analysis</title><p>RNA/miRNA from cells was isolated using GeneMATRIX Universal RNA/miRNA Purification Kit (EURx, Gda&#324;sk, Poland) according to the provider&#8217;s instructions. RNA from matched pairs of ccRCC/control was retrieved from the Tissue Bank.</p><p>For real-time quantitative polymerase chain reaction (qPCR) gene expression analysis, cDNA was synthesized using Transcriptor First Strand cDNA Synthesis Kit (Roche Diagnostics, Mannheim, Germany) (for RNA isolated from clinical samples) or RevertAid<sup>TM</sup> H Minus First Strand cDNA Synthesis Kit (Thermo Fisher Scientific, Rockford, IL, USA) (for RNA isolated from cell cultures) following manufacturer&#8217;s instruction. qPCR reactions were performed using SYBR<sup>&#174;</sup> Green Master Mix (Roche, Mannheim, Germany) and specific primers. Primers sequences used in the study are presented in <xref rid="ijms-26-08618-t0A2" ref-type="table">Table A2</xref> in <xref rid="app1-ijms-26-08618" ref-type="app">Appendix A</xref>.</p><p>For real-time qPCR microRNA expression analysis, cDNA was synthesized using miRCURY LNA<sup>TM</sup> Universal cDNA Synthesis Kit (Qiagen, Germantown, MD, USA) according to the provider&#8217;s protocol. qPCR reactions were performed using ExiLENT SYBR<sup>&#174;</sup> Green Master Mix (Qiagen, Germantown, MD, USA) and miRCURY LNA<sup>TM</sup> miRNA PCR primers (Qiagen, Germantown, MD, USA). Primers sequences used in the study are presented in <xref rid="ijms-26-08618-t0A3" ref-type="table">Table A3</xref> in <xref rid="app1-ijms-26-08618" ref-type="app">Appendix A</xref>.</p></sec><sec id="sec4dot5-ijms-26-08618"><title>4.5. Total Protein Isolation and Western Blotting Analysis</title><p>Tumor tissues and cultured cells were homogenized in RIPA buffer (Thermo Fisher) supplemented with protease inhibitors (Roche) and &#946;-mercaptoethanol. Protein extracts (30 &#181;g from tissue or 25 &#181;g from culture cells) were separated on a 12% SDS-PAGE gel and transferred to a nitrocellulose membrane (Thermo Fisher). Membranes were blocked in 5% non-fat milk (in TBST) and incubated with primary antibodies: mouse-anti-MCM7 (Novus Biologicals, #H00004176-M01; 1:500, Centennial, CO, USA), mouse-anti-&#946;-actin (Abcam, #ab6276; 1:10,000, Cambridge, UK), followed by secondary antibody incubation (anti-mouse goat, Dako; 1:10,000, Santa Clara, CA, USA). Signals were visualized using ECL substrate (SuperSignal<sup>TM</sup> West Pico PLUS, ThermoFisher) and developed on X-ray film (Kodak, Rochester, NY, USA). &#946;-actin was used as a loading control.</p></sec><sec id="sec4dot6-ijms-26-08618"><title>4.6. Functional Assays</title><sec id="sec4dot6dot1-ijms-26-08618"><title>4.6.1. Luciferase Reporter Assay</title><p>Luciferase activity was determined 48 h after transfection using the Dual-Glo Luciferase Reporter Assay System (Promega, Madison, WI, USA) as described [<xref rid="B20-ijms-26-08618" ref-type="bibr">20</xref>]. Briefly, Caki-2 cells were co-transfected with constructs (pmirGLO Dual-Luciferase miRNA Target Expression Vector (Promega)) containing miRNAs binding sites in the 3&#8242;UTR of target genes or control vector and miRCURY LNA microRNA mimics or negative control (Qiagen, Germantown, MD, USA). Luciferase activity was normalized to Renilla and presented as relative luciferase activity.</p></sec><sec id="sec4dot6dot2-ijms-26-08618"><title>4.6.2. BrdU Incorporation Assay</title><p>Cell proliferation was measured 72 h after transfection using the BrdU incorporation assay according to the manufacturer&#8217;s instructions.</p></sec><sec id="sec4dot6dot3-ijms-26-08618"><title>4.6.3. Caspase-3/7 Activity Assay</title><p>Caspase-3/7 activity was measured 72 h after transfection using the Caspase-Glo<sup>&#174;</sup> 3/7 Assay Kit (Promega, Madison, WI, USA) following the manufacturer&#8217;s instructions.</p></sec></sec><sec id="sec4dot7-ijms-26-08618"><title>4.7. Bioinformatics, TCGA, and CPTAC Data Analysis</title><p>To identify the putative miRNA target genes, we used several prediction tools, including miRDB [<xref rid="B83-ijms-26-08618" ref-type="bibr">83</xref>,<xref rid="B84-ijms-26-08618" ref-type="bibr">84</xref>], mirDIP [<xref rid="B85-ijms-26-08618" ref-type="bibr">85</xref>,<xref rid="B86-ijms-26-08618" ref-type="bibr">86</xref>], miRSystem [<xref rid="B87-ijms-26-08618" ref-type="bibr">87</xref>], and TargetScan [<xref rid="B88-ijms-26-08618" ref-type="bibr">88</xref>] to visualize the miRNA binding sites in the 3&#8242;UTR of selected target genes.</p><p>To verify our findings in the larger ccRCC cohort, we utilized datasets from The Cancer Genome Atlas (TCGA) and the Clinical Proteomic Tumor Analysis Consortium (CPTAC).</p><p>RNA-seq data for KIRC cancer were obtained from TCGA via the TCGAbiolinks package [<xref rid="B89-ijms-26-08618" ref-type="bibr">89</xref>]. For the analysis, samples labelled as &#8220;Primary Tumor&#8221; and &#8220;Solid Tissue Normal&#8221; were selected. The final dataset consisted of 541 tumor samples and 72 normal samples. Raw count data from the TCGA-KIRC cohort were obtained using the TCGAbiolinks package and processed in R (v4.5.1) [<xref rid="B90-ijms-26-08618" ref-type="bibr">90</xref>]. Genes were filtered to retain only entries annotated as <italic toggle="yes">protein_coding</italic>, based on Ensembl metadata. One sample labeled as &#8220;Additional&#8212;New Primary&#8221; (barcode: TCGA-DV-A4W0-05A-11R-A266-07) was excluded due to inconsistent classification. A variance stabilizing transformation (VST) was applied to raw counts using the vst function from the DESeq2 package (v1.40.2) [<xref rid="B91-ijms-26-08618" ref-type="bibr">91</xref>], yielding normalized expression values suitable for visualization and hypothesis testing. Samples were stratified according to TNM classification into two clinical groups: Group 1 (Stages I&#8211;II; N1/T1; N1 = 31, T1 = 294) and Group 2 (Stages III&#8211;IV; N2/T2; N2 = 27, T2 = 158). An additional combined category included all tumor and normal samples (Nall/Tall; Nall = 72, Tall = 541). mRNA expression comparisons between tumor and normal samples were performed using the Wilcoxon rank-sum test, and corresponding <italic toggle="yes">p</italic>-values were used to assess statistical significance. Selected genes of interest were visualized using boxplots and statistical annotations generated with ggplot2 [<xref rid="B92-ijms-26-08618" ref-type="bibr">92</xref>].</p><p>Proteomics data for clear cell Renal Cell Carcinoma (CCRCC) were obtained from the LinkedOmics database [<xref rid="B93-ijms-26-08618" ref-type="bibr">93</xref>], specifically from the CPTAC CCRCC cohort included in the CPTAC pan-cancer initiative [<xref rid="B94-ijms-26-08618" ref-type="bibr">94</xref>]. The dataset included quantitative protein expression profiles derived from mass spectrometry-based proteomics and consisted of 103 tumor samples and 80 normal samples. Only samples with MCM7 quantified were selected for further analysis (80 tumor samples and 80 normal samples). Samples were labelled according to TNM classification into two clinical groups: Group 1 (Stages I-II; N1/T1; N1 = 40, T1 = 40) and Group 2 (Stages III-IV; N2/T2; N2 = 40, T2 = 40). An additional combined category included all tumor and normal samples (Nall/Tall; Nall = 80, Tall = 80). Protein abundance values from paired tumors and adjacent normal tissues were merged and filtered to retain proteins with non-missing values across all samples. Patients were stratified based on TNM stage classification (Stage I&#8211;II vs. Stage III&#8211;IV), allowing stage-specific comparisons. Protein expression levels between tumor and normal samples were compared using the Wilcoxon rank-sum test, applied independently for each protein.</p></sec><sec id="sec4dot8-ijms-26-08618"><title>4.8. Statistical Analysis and Data Presentation</title><p>All experiments were conducted in at least three independent biological repetitions, each performed in triplicate, unless otherwise indicated in the figure legends. GraphPad Prism 10 (GraphPad Software Inc., Boston, MA, USA) was used for statistical analysis. Data distribution was examined by the Shapiro&#8211;Wilk test. Differences between groups were measured by <italic toggle="yes">t</italic>-test, Kruskal&#8211;Wallis test, or Analysis of Variance (ANOVA), followed by appropriate post-hoc comparison. For the analysis of clinical samples, the Wilcoxon signed-rank test was used.</p></sec></sec><sec sec-type="conclusions" id="sec5-ijms-26-08618"><title>5. Conclusions</title><p>Taken together, our findings support an important role for MCM7 and the miR-106b-25 cluster in renal cancer. MCM7 is upregulated in renal cancer at the mRNA and protein levels, and its dysregulation contributes to cell proliferation and caspase-3/7 activity. MicroRNAs from the intragenic miR-106b-25 cluster regulate the expression of cancer-related genes found to be dysregulated in renal cancer and modulate caspase-3/7 activity. These findings underscore the oncogenic potential of the MCM7 and miR-106b-25 cluster, supporting its relevance as a candidate for future diagnostic and therapeutic strategies in RCC.</p></sec></body><back><ack><title>Acknowledgments</title><p>We thank our colleagues from the Department of Biochemistry and Molecular Biology at the Centre of Postgraduate Medical Education (Warsaw, Poland) for assistance with RNA and protein preparation. We thank J.A. Copland from Mayo Foundation for Medical Education and Research for providing the KIJ-265T cell line, and Zbigniew Ta&#324;ski (Masovian Specialist Hospital, Ostroleka, Poland) for providing tissue specimens deposited in the Local Tissue Bank at the Department of Biochemistry and Molecular Biology, Centre of Postgraduate Medical Education (Warsaw, Poland).</p></ack><fn-group><fn><p><bold>Disclaimer/Publisher&#8217;s Note:</bold> The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.</p></fn></fn-group><notes><title>Author Contributions</title><p>Conceptualization, K.M.G.; methodology, K.M.G. and B.H.; validation, K.M.G. and B.H.; formal analysis, K.M.G. and B.H.; investigation, K.M.G. and B.H.; resources, K.M.G.; data curation, K.M.G.; writing&#8212;original draft preparation, K.M.G.; writing&#8212;review and editing, K.M.G. and B.H.; visualization, K.M.G. and B.H.; supervision, K.M.G.; funding acquisition, K.M.G. All authors have read and agreed to the published version of the manuscript.</p></notes><notes><title>Institutional Review Board Statement</title><p>Collection and sampling were authorized by the Institutional Bioethics Committee of the Centre of Postgraduate Medical Education (Approval number and date: 18/PB/2012&#8212;29 February 2012, 75/PB-A/2014&#8212;29 October 2014, 47/PB/2017&#8212;10 May 2017).</p></notes><notes><title>Informed Consent Statement</title><p>Informed consent was obtained from all subjects involved in the study.</p></notes><notes notes-type="COI-statement"><title>Conflicts of Interest</title><p>The authors declare no conflicts of interest.</p></notes><app-group><app id="app1-ijms-26-08618"><title>Appendix A</title><table-wrap position="anchor" id="ijms-26-08618-t0A1" orientation="portrait"><object-id pub-id-type="pii">ijms-26-08618-t0A1_Table A1</object-id><label>Table A1</label><caption><p>List of miRCURY LNA <sup>TM</sup> miRNA mimic/inhibitor/control nucleotides used in the study (purchased from Qiagen (Hilden, Germany)).</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Product Name/Target Name</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Cat. Number</th></tr></thead><tbody><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">hsa-miR-25-3p miRCURY LNA miRNA Mimic</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">339173_YM00470873-ADA</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">hsa-miR-93-5p miRCURY LNA miRNA Mimic</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">339173_YM00471046-ADA</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">hsa-miR-106b-5p miRCURY LNA miRNA Mimic</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">339173_YM00471973-ADA</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Negative Control miRCURY LNA miRNA Mimic</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">339173_YM00479902-ADA</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">hsa-miR-25-3p miRCURY LNA miRNA Inhibitor</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">339121_YI04100613-ADA</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">hsa-miR-93-5p miRCURY LNA miRNA Inhibitor</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">339121_YI04101031-ADA</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">hsa-miR-106b-5p miRCURY LNA miRNA Inhibitor</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">339121_YI04100930-ADA</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Negative Control miRCURY LNA miRNA Inhibitor</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">339126_YI00199006-ADA</td></tr></tbody></table></table-wrap><table-wrap position="anchor" id="ijms-26-08618-t0A2" orientation="portrait"><object-id pub-id-type="pii">ijms-26-08618-t0A2_Table A2</object-id><label>Table A2</label><caption><p>List of primers used for real-time qPCR analysis.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Gene Name Abbreviation</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Nucleotide Sequence (5&#8242; &#8594; 3&#8242;)</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Source</th></tr></thead><tbody><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">18sRNA</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">F: GTAACCCGTTGAACCCCATT<break/>R: CCATCCAATCGGTAGTAGCG</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B95-ijms-26-08618" ref-type="bibr">95</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">ACTB</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">F: CCAGCTCACCATGGATGATG<break/>R: ATGCCGGAGCCGTTGTC</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B96-ijms-26-08618" ref-type="bibr">96</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">ACTB</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">F: CGGCATCGTCACCAACTG<break/>R: GCTGGGGTGTTGAAGGTCTC</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B97-ijms-26-08618" ref-type="bibr">97</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">ATXN1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">F: ACAGTGGAACCTATGCCAGC<break/>R: GTTGGCCAGCAGAGTGGAAT</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">This study</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">BRMS1L</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">F: GGCACAGCATTGATATTACCTCA<break/>R: TATGGACCTGAAACAACAACTGG</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B69-ijms-26-08618" ref-type="bibr">69</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">COL19A1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">F: GTGACCCGATTGCACTTCC<break/>R: TGGCCCTATATCACCCTTCCG</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">This study</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">CPEB3</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">F: CCCTTCTCCAGCAACGTGAT<break/>R: TCATAGGGCCTACTCCGGTC</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">This study</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">DOCK4</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">F: TCCTACTTTTACCTCGCAGTC<break/>R: TCCCAGCTTCCTTGTTATGGAT</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">This study</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">DNAJB9</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">F: CCAAAATCGGCATCAGAGCG<break/>R: ATTTTGCTTCAGCATCCGGG</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">This study</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">KIF3B</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">F: CTACCAACATGAACGAGCAC<break/>R: GGTTCAATTTTCCTACACGGAT</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">This study</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">MCM7</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">F: CCCCTCCCAGTTTGAACCTCT <break/>R: TCGCCTCATCTCCACGTATGCT </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">This study</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NEDD4L</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">F: TGCCCAAACCACCCCGTCAT<break/>R: TCAGGACTGCCCCATTGCTC</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B98-ijms-26-08618" ref-type="bibr">98</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NFIB95</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">F: GCCCATAACCCAGGGAACTG<break/>R: CCTCTGAAGATTGACCCCCG</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">This study</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">PTPRJ</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">F: CTGTTTCCATCAGTCCAACC<break/>R: ATGAAGTCGCTGGACGTAAG</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B99-ijms-26-08618" ref-type="bibr">99</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">RBL2</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">F: CAACAATGGGCAAACGGTAAC<break/>R: GCCACTTGACCAGGGACTTG</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B100-ijms-26-08618" ref-type="bibr">100</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">SMAD7</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">F: ATGATCTACCTCAGGGGAAT<break/>R: GACTTGATGAAGATGGGGTA</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B101-ijms-26-08618" ref-type="bibr">101</xref>]</td></tr></tbody></table></table-wrap><table-wrap position="anchor" id="ijms-26-08618-t0A3" orientation="portrait"><object-id pub-id-type="pii">ijms-26-08618-t0A3_Table A3</object-id><label>Table A3</label><caption><p>List of miRCURY LNA <sup>TM</sup> miRNA PCR Assays (LNA primers) used in the study (purchased from Qiagen (Hilden, Germany)).</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Product Name/Target Name</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Cat. Number</th></tr></thead><tbody><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">hsa-miR-25-3p miRCURY LNA miRNA PCR Assay</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">339306_YP00204361</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">hsa-miR-93-5p miRCURY LNA miRNA PCR Assay</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">339306_YP00204715</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">hsa-miR-106b-5p miRCURY LNA miRNA PCR Assay</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">339306_YP00205884</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">SNORD44(hsa) miRCURY LNA miRNA PCR Assay</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">339306_YP00203902</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">hsa-miR-28-5p miRCURY LNA miRNA PCR Assay</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">339306_YP00204322</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">hsa-miR-103a-3p miRCURY LNA miRNA PCR Assay</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">339306_YP00204063</td></tr></tbody></table></table-wrap><table-wrap position="anchor" id="ijms-26-08618-t0A4" orientation="portrait"><object-id pub-id-type="pii">ijms-26-08618-t0A4_Table A4</object-id><label>Table A4</label><caption><p>List of genes predicted as common targets for all three microRNAs (miR-25-3p, miR-93-5p, miR-106b-5p).</p></caption><table frame="hsides" rules="groups"><tbody><tr><td align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">ABCG4 AFF1 AFF4 ANKIB1 ANKRD13C ATXN1 B3GALT2 BCL11B BCL2L11 BMPR2 BRMS1L CD69 C17ORF39 CHRM2 CHD9 CIC COL19A1 CPEB3 DLGAP2 DNAJB9 DNAJC27 DOCK4 E2F3 EGR2 FAM126B FAM117B FAM19A1 FCHO2 FNDC3B FRS2 FXR1 GATAD2B HEG1 GIT2 GNS GOLGA1 GPR137C IKZF4 KIAA1128 KIF3B LUZP1 JOSD1 KAT2B LYST MCL1 MTF1 MYT1L NEDD4L NFAT5 NFIB NR4A3 ODZ1 OTUD4 PAFAH1B1 PALLD PHTF2 PITPNA PIP5K3 PTEN PTPRD PTPRJ PTPRO RAB8B RBL2 RGL1 RNF38 RSBN1 RGMA SDC2 SERTAD2 SH3PXD2A SIRPA SMAD6 SMAD7 SGK269 SNF1LK SNIP SOBP SOCS6 SOX4 TTC9 UBE2W USP28 WASL WDFY3 XRN1 TWF1 UBASH3B UBE2W USP28 XRN1 ZNF148</td></tr></tbody></table></table-wrap><fig position="anchor" id="ijms-26-08618-f0A1" orientation="portrait"><label>Figure A1</label><caption><p>Western blot analysis showing MCM7 gene silencing efficiency. Caki-2 cells were transfected with synthetic siRNA targeting MCM7 (siMCM7) or control oligonucleotides (siCTRL). MCM7 protein levels were evaluated 72 h post-transfection. &#946;-actin was used as a loading control. The results from one biological experiment performed in two replicates are presented.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="ijms-26-08618-g0A1.jpg"/></fig><fig position="anchor" id="ijms-26-08618-f0A2" orientation="portrait"><label>Figure A2</label><caption><p>Western blot detection of MCM7 in RCC cells after transfection with siRNA and microRNA inhibitors. Caki-2 (<bold>A</bold>) and KIJ-265T (<bold>B</bold>) cells were co-transfected with siRNA targeting MCM7 (siMCM7) and/or a mix of microRNA inhibitors (Inh25/93/106), as well as corresponding controls (siCTRL, miR-inhibitor control&#8211;InhCTRL). MCM7 protein expression was evaluated 72 h post-transfection. &#946;-actin was used as a loading control. Results from one biological experiment are shown.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="ijms-26-08618-g0A2.jpg"/></fig></app></app-group><ref-list><title>References</title><ref id="B1-ijms-26-08618"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bray</surname><given-names>F.</given-names></name><name name-style="western"><surname>Laversanne</surname><given-names>M.</given-names></name><name name-style="western"><surname>Sung</surname><given-names>H.</given-names></name><name name-style="western"><surname>Ferlay</surname><given-names>J.</given-names></name><name name-style="western"><surname>Siegel</surname><given-names>R.L.</given-names></name><name name-style="western"><surname>Soerjomataram</surname><given-names>I.</given-names></name><name name-style="western"><surname>Jemal</surname><given-names>A.</given-names></name></person-group><article-title>Global Cancer Statistics 2022: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries</article-title><source>CA A Cancer J. Clin.</source><year>2024</year><volume>74</volume><fpage>229</fpage><lpage>263</lpage><pub-id pub-id-type="doi">10.3322/caac.21834</pub-id><pub-id pub-id-type="pmid">38572751</pub-id></element-citation></ref><ref id="B2-ijms-26-08618"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hsieh</surname><given-names>J.J.</given-names></name><name name-style="western"><surname>Purdue</surname><given-names>M.P.</given-names></name><name name-style="western"><surname>Signoretti</surname><given-names>S.</given-names></name><name name-style="western"><surname>Swanton</surname><given-names>C.</given-names></name><name name-style="western"><surname>Albiges</surname><given-names>L.</given-names></name><name name-style="western"><surname>Schmidinger</surname><given-names>M.</given-names></name><name name-style="western"><surname>Heng</surname><given-names>D.Y.</given-names></name><name name-style="western"><surname>Larkin</surname><given-names>J.</given-names></name><name name-style="western"><surname>Ficarra</surname><given-names>V.</given-names></name></person-group><article-title>Renal Cell Carcinoma</article-title><source>Nat. Rev. Dis. Primers</source><year>2017</year><volume>3</volume><fpage>17009</fpage><pub-id pub-id-type="doi">10.1038/nrdp.2017.9</pub-id><pub-id pub-id-type="pmid">28276433</pub-id><pub-id pub-id-type="pmcid">PMC5936048</pub-id></element-citation></ref><ref id="B3-ijms-26-08618"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Roberto</surname><given-names>M.</given-names></name><name name-style="western"><surname>Botticelli</surname><given-names>A.</given-names></name><name name-style="western"><surname>Panebianco</surname><given-names>M.</given-names></name><name name-style="western"><surname>Aschelter</surname><given-names>A.M.</given-names></name><name name-style="western"><surname>Gelibter</surname><given-names>A.</given-names></name><name name-style="western"><surname>Ciccarese</surname><given-names>C.</given-names></name><name name-style="western"><surname>Minelli</surname><given-names>M.</given-names></name><name name-style="western"><surname>Nuti</surname><given-names>M.</given-names></name><name name-style="western"><surname>Santini</surname><given-names>D.</given-names></name><name name-style="western"><surname>Laghi</surname><given-names>A.</given-names></name><etal/></person-group><article-title>Metastatic Renal Cell Carcinoma Management: From Molecular Mechanism to Clinical Practice</article-title><source>Front. Oncol.</source><year>2021</year><volume>11</volume><elocation-id>657639</elocation-id><pub-id pub-id-type="doi">10.3389/fonc.2021.657639</pub-id><pub-id pub-id-type="pmid">33968762</pub-id><pub-id pub-id-type="pmcid">PMC8100507</pub-id></element-citation></ref><ref id="B4-ijms-26-08618"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jiang</surname><given-names>A.</given-names></name><name name-style="western"><surname>Zapa&#322;a</surname><given-names>&#321;.</given-names></name><name name-style="western"><surname>Qu</surname><given-names>L.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>L.</given-names></name></person-group><article-title>Editorial: Establishment of Marker Models for Molecular Typing of Renal Cell Carcinoma</article-title><source>Front. Oncol.</source><year>2023</year><volume>13</volume><elocation-id>1236980</elocation-id><pub-id pub-id-type="doi">10.3389/fonc.2023.1236980</pub-id><pub-id pub-id-type="pmid">37492475</pub-id><pub-id pub-id-type="pmcid">PMC10364634</pub-id></element-citation></ref><ref id="B5-ijms-26-08618"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Choi</surname><given-names>S.H.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>Y.-W.</given-names></name><name name-style="western"><surname>Panian</surname><given-names>J.</given-names></name><name name-style="western"><surname>Yuen</surname><given-names>K.</given-names></name><name name-style="western"><surname>McKay</surname><given-names>R.R.</given-names></name></person-group><article-title>Emerging Innovative Treatment Strategies for Advanced Clear Cell Renal Cell Carcinoma</article-title><source>Oncol.</source><year>2025</year><volume>30</volume><fpage>oyae276</fpage><pub-id pub-id-type="doi">10.1093/oncolo/oyae276</pub-id><pub-id pub-id-type="pmcid">PMC11954509</pub-id><pub-id pub-id-type="pmid">39401004</pub-id></element-citation></ref><ref id="B6-ijms-26-08618"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Qu</surname><given-names>K.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Fan</surname><given-names>H.</given-names></name><name name-style="western"><surname>Li</surname><given-names>J.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>J.</given-names></name><name name-style="western"><surname>Li</surname><given-names>P.</given-names></name><name name-style="western"><surname>Liang</surname><given-names>Z.</given-names></name><name name-style="western"><surname>An</surname><given-names>H.</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Lin</surname><given-names>Q.</given-names></name><etal/></person-group><article-title>MCM7 Promotes Cancer Progression through Cyclin D1-Dependent Signaling and Serves as a Prognostic Marker for Patients with Hepatocellular Carcinoma</article-title><source>Cell Death Dis.</source><year>2017</year><volume>8</volume><fpage>e2603</fpage><pub-id pub-id-type="doi">10.1038/cddis.2016.352</pub-id><pub-id pub-id-type="pmid">28182015</pub-id><pub-id pub-id-type="pmcid">PMC5386449</pub-id></element-citation></ref><ref id="B7-ijms-26-08618"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhao</surname><given-names>M.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>C.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Mi</surname><given-names>J.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Zuo</surname><given-names>L.</given-names></name><name name-style="western"><surname>Geng</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Song</surname><given-names>X.</given-names></name><name name-style="western"><surname>Ge</surname><given-names>S.</given-names></name><etal/></person-group><article-title>miR-107 Regulates the Effect of MCM7 on the Proliferation and Apoptosis of Colorectal Cancer via the PAK2 Pathway</article-title><source>Biochem. Pharmacol.</source><year>2021</year><volume>190</volume><elocation-id>114610</elocation-id><pub-id pub-id-type="doi">10.1016/j.bcp.2021.114610</pub-id><pub-id pub-id-type="pmid">34010598</pub-id></element-citation></ref><ref id="B8-ijms-26-08618"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhou</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>X.</given-names></name><name name-style="western"><surname>Cao</surname><given-names>L.</given-names></name><name name-style="western"><surname>Li</surname><given-names>B.</given-names></name><name name-style="western"><surname>Sui</surname><given-names>C.</given-names></name><name name-style="western"><surname>Li</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Yin</surname><given-names>Z.</given-names></name></person-group><article-title>MCM7 Expression Predicts Post-operative Prognosis for Hepatocellular Carcinoma</article-title><source>Liver Int.</source><year>2012</year><volume>32</volume><fpage>1505</fpage><lpage>1509</lpage><pub-id pub-id-type="doi">10.1111/j.1478-3231.2012.02846.x</pub-id><pub-id pub-id-type="pmid">22784096</pub-id></element-citation></ref><ref id="B9-ijms-26-08618"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>Y.-Z.</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>Y.-Y.</given-names></name><name name-style="western"><surname>Hao</surname><given-names>J.-J.</given-names></name><name name-style="western"><surname>Lu</surname><given-names>S.-S.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>T.-T.</given-names></name><name name-style="western"><surname>Shang</surname><given-names>L.</given-names></name><name name-style="western"><surname>Cao</surname><given-names>J.</given-names></name><name name-style="western"><surname>Song</surname><given-names>X.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>B.-S.</given-names></name><name name-style="western"><surname>Cai</surname><given-names>Y.</given-names></name><etal/></person-group><article-title>Prognostic Significance of MCM7 Expression in the Bronchial Brushings of Patients with Non-Small Cell Lung Cancer (NSCLC)</article-title><source>Lung Cancer</source><year>2012</year><volume>77</volume><fpage>176</fpage><lpage>182</lpage><pub-id pub-id-type="doi">10.1016/j.lungcan.2012.03.001</pub-id><pub-id pub-id-type="pmid">22456526</pub-id></element-citation></ref><ref id="B10-ijms-26-08618"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Garbicz</surname><given-names>F.</given-names></name><name name-style="western"><surname>Mehlich</surname><given-names>D.</given-names></name><name name-style="western"><surname>Rak</surname><given-names>B.</given-names></name><name name-style="western"><surname>Sajjad</surname><given-names>E.</given-names></name><name name-style="western"><surname>Maksymowicz</surname><given-names>M.</given-names></name><name name-style="western"><surname>Paskal</surname><given-names>W.</given-names></name><name name-style="western"><surname>Zieli&#324;ski</surname><given-names>G.</given-names></name><name name-style="western"><surname>W&#322;odarski</surname><given-names>P.K.</given-names></name></person-group><article-title>Increased Expression of the microRNA 106b~25 Cluster and Its Host Gene MCM7 in Corticotroph Pituitary Adenomas Is Associated with Tumor Invasion and Crooke&#8217;s Cell Morphology</article-title><source>Pituitary</source><year>2017</year><volume>20</volume><fpage>450</fpage><lpage>463</lpage><pub-id pub-id-type="doi">10.1007/s11102-017-0805-y</pub-id><pub-id pub-id-type="pmid">28432562</pub-id><pub-id pub-id-type="pmcid">PMC5508039</pub-id></element-citation></ref><ref id="B11-ijms-26-08618"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Alshahrani</surname><given-names>M.Y.</given-names></name><name name-style="western"><surname>Alshahrani</surname><given-names>K.M.</given-names></name><name name-style="western"><surname>Tasleem</surname><given-names>M.</given-names></name><name name-style="western"><surname>Akeel</surname><given-names>A.</given-names></name><name name-style="western"><surname>Almeleebia</surname><given-names>T.M.</given-names></name><name name-style="western"><surname>Ahmad</surname><given-names>I.</given-names></name><name name-style="western"><surname>Asiri</surname><given-names>M.</given-names></name><name name-style="western"><surname>Alshahrani</surname><given-names>N.A.</given-names></name><name name-style="western"><surname>Alabdallah</surname><given-names>N.M.</given-names></name><name name-style="western"><surname>Saeed</surname><given-names>M.</given-names></name></person-group><article-title>Computational Screening of Natural Compounds for Identification of Potential Anti-Cancer Agents Targeting MCM7 Protein</article-title><source>Molecules</source><year>2021</year><volume>26</volume><elocation-id>5878</elocation-id><pub-id pub-id-type="doi">10.3390/molecules26195878</pub-id><pub-id pub-id-type="pmid">34641424</pub-id><pub-id pub-id-type="pmcid">PMC8510405</pub-id></element-citation></ref><ref id="B12-ijms-26-08618"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gou</surname><given-names>K.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>J.</given-names></name><name name-style="western"><surname>Feng</surname><given-names>X.</given-names></name><name name-style="western"><surname>Li</surname><given-names>H.</given-names></name><name name-style="western"><surname>Yuan</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Xing</surname><given-names>C.</given-names></name></person-group><article-title>Expression of Minichromosome Maintenance Proteins (MCM) and Cancer Prognosis: A Meta-Analysis</article-title><source>J. Cancer</source><year>2018</year><volume>9</volume><fpage>1518</fpage><lpage>1526</lpage><pub-id pub-id-type="doi">10.7150/jca.22691</pub-id><pub-id pub-id-type="pmid">29721062</pub-id><pub-id pub-id-type="pmcid">PMC5929097</pub-id></element-citation></ref><ref id="B13-ijms-26-08618"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Samad</surname><given-names>A.</given-names></name><name name-style="western"><surname>Parvez</surname><given-names>M.d.A.K.</given-names></name><name name-style="western"><surname>Huq</surname><given-names>M.d.A.</given-names></name><name name-style="western"><surname>Rahman</surname><given-names>M.d.S.</given-names></name></person-group><article-title>Transcriptional Expression and Prognostic Roles of MCM7 in Human Bladder, Breast, and Lung Cancers: A Multi-Omics Analysis</article-title><source>Netw. Model. Anal. Health Inform. Bioinforma</source><year>2022</year><volume>12</volume><elocation-id>8</elocation-id><pub-id pub-id-type="doi">10.1007/s13721-022-00405-y</pub-id></element-citation></ref><ref id="B14-ijms-26-08618"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>H.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Cheng</surname><given-names>A.S.L.</given-names></name><name name-style="western"><surname>Yu</surname><given-names>J.</given-names></name><name name-style="western"><surname>To</surname><given-names>K.F.</given-names></name><name name-style="western"><surname>Kang</surname><given-names>W.</given-names></name></person-group><article-title>MCM Family in Gastrointestinal Cancer and Other Malignancies: From Functional Characterization to Clinical Implication</article-title><source>Biochim. Et Biophys. Acta (BBA)-Rev. Cancer</source><year>2020</year><volume>1874</volume><elocation-id>188415</elocation-id><pub-id pub-id-type="doi">10.1016/j.bbcan.2020.188415</pub-id><pub-id pub-id-type="pmid">32822825</pub-id></element-citation></ref><ref id="B15-ijms-26-08618"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Poliseno</surname><given-names>L.</given-names></name><name name-style="western"><surname>Salmena</surname><given-names>L.</given-names></name><name name-style="western"><surname>Riccardi</surname><given-names>L.</given-names></name><name name-style="western"><surname>Fornari</surname><given-names>A.</given-names></name><name name-style="western"><surname>Song</surname><given-names>M.S.</given-names></name><name name-style="western"><surname>Hobbs</surname><given-names>R.M.</given-names></name><name name-style="western"><surname>Sportoletti</surname><given-names>P.</given-names></name><name name-style="western"><surname>Varmeh</surname><given-names>S.</given-names></name><name name-style="western"><surname>Egia</surname><given-names>A.</given-names></name><name name-style="western"><surname>Fedele</surname><given-names>G.</given-names></name><etal/></person-group><article-title>Identification of the miR-106b~25 MicroRNA Cluster as a Proto-Oncogenic PTEN-Targeting Intron That Cooperates with Its Host Gene MCM7 in Transformation</article-title><source>Sci. Signal.</source><year>2010</year><volume>3</volume><elocation-id>ra29</elocation-id><pub-id pub-id-type="doi">10.1126/scisignal.2000594</pub-id><pub-id pub-id-type="pmid">20388916</pub-id><pub-id pub-id-type="pmcid">PMC2982149</pub-id></element-citation></ref><ref id="B16-ijms-26-08618"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kim</surname><given-names>T.</given-names></name><name name-style="western"><surname>Croce</surname><given-names>C.M.</given-names></name></person-group><article-title>MicroRNA: Trends in Clinical Trials of Cancer Diagnosis and Therapy Strategies</article-title><source>Exp. Mol. Med.</source><year>2023</year><volume>55</volume><fpage>1314</fpage><lpage>1321</lpage><pub-id pub-id-type="doi">10.1038/s12276-023-01050-9</pub-id><pub-id pub-id-type="pmid">37430087</pub-id><pub-id pub-id-type="pmcid">PMC10394030</pub-id></element-citation></ref><ref id="B17-ijms-26-08618"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ju</surname><given-names>J.</given-names></name></person-group><article-title>Challenges and Opportunities in microRNA-Based Cancer Therapeutics</article-title><source>Cell Rep. Med.</source><year>2025</year><volume>6</volume><fpage>102057</fpage><pub-id pub-id-type="doi">10.1016/j.xcrm.2025.102057</pub-id><pub-id pub-id-type="pmid">40239629</pub-id><pub-id pub-id-type="pmcid">PMC12047499</pub-id></element-citation></ref><ref id="B18-ijms-26-08618"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bergantim</surname><given-names>R.</given-names></name><name name-style="western"><surname>Peixoto da Silva</surname><given-names>S.</given-names></name><name name-style="western"><surname>Pinto</surname><given-names>V.</given-names></name><name name-style="western"><surname>Pereira</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Sousa</surname><given-names>D.</given-names></name><name name-style="western"><surname>Trigo</surname><given-names>F.</given-names></name><name name-style="western"><surname>Matthiesen</surname><given-names>R.</given-names></name><name name-style="western"><surname>Guimar&#227;es</surname><given-names>J.E.</given-names></name><name name-style="western"><surname>Vasconcelos</surname><given-names>M.H.</given-names></name></person-group><article-title>MicroRNA-665 and Its Potential Role in Drug Response and Survival Outcomes in Multiple Myeloma: A Preliminary Study</article-title><source>Front. Pharmacol.</source><year>2025</year><volume>16</volume><elocation-id>1465814</elocation-id><pub-id pub-id-type="doi">10.3389/fphar.2025.1465814</pub-id><pub-id pub-id-type="pmid">40255571</pub-id><pub-id pub-id-type="pmcid">PMC12006192</pub-id></element-citation></ref><ref id="B19-ijms-26-08618"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Verboon</surname><given-names>L.J.</given-names></name><name name-style="western"><surname>Obulkasim</surname><given-names>A.</given-names></name><name name-style="western"><surname>De Rooij</surname><given-names>J.D.E.</given-names></name><name name-style="western"><surname>Katsman-Kuipers</surname><given-names>J.E.</given-names></name><name name-style="western"><surname>Sonneveld</surname><given-names>E.</given-names></name><name name-style="western"><surname>Baruchel</surname><given-names>A.</given-names></name><name name-style="western"><surname>Trka</surname><given-names>J.</given-names></name><name name-style="western"><surname>Reinhardt</surname><given-names>D.</given-names></name><name name-style="western"><surname>Pieters</surname><given-names>R.</given-names></name><name name-style="western"><surname>Cloos</surname><given-names>J.</given-names></name><etal/></person-group><article-title>MicroRNA-106b~25 Cluster Is Upregulated in Relapsed <italic toggle="yes">MLL</italic> -Rearranged Pediatric Acute Myeloid Leukemia</article-title><source>Oncotarget</source><year>2016</year><volume>7</volume><fpage>48412</fpage><lpage>48422</lpage><pub-id pub-id-type="doi">10.18632/oncotarget.10270</pub-id><pub-id pub-id-type="pmid">27351222</pub-id><pub-id pub-id-type="pmcid">PMC5217027</pub-id></element-citation></ref><ref id="B20-ijms-26-08618"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bogus&#322;awska</surname><given-names>J.</given-names></name><name name-style="western"><surname>Rodzik</surname><given-names>K.</given-names></name><name name-style="western"><surname>Pop&#322;awski</surname><given-names>P.</given-names></name><name name-style="western"><surname>K&#281;dzierska</surname><given-names>H.</given-names></name><name name-style="western"><surname>Rybicka</surname><given-names>B.</given-names></name><name name-style="western"><surname>Sok&#243;&#322;</surname><given-names>E.</given-names></name><name name-style="western"><surname>Ta&#324;ski</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Piekie&#322;ko-Witkowska</surname><given-names>A.</given-names></name></person-group><article-title>TGF-&#914;1 Targets a microRNA Network That Regulates Cellular Adhesion and Migration in Renal Cancer</article-title><source>Cancer Lett.</source><year>2018</year><volume>412</volume><fpage>155</fpage><lpage>169</lpage><pub-id pub-id-type="doi">10.1016/j.canlet.2017.10.019</pub-id><pub-id pub-id-type="pmid">29079415</pub-id></element-citation></ref><ref id="B21-ijms-26-08618"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Guarnieri</surname><given-names>A.L.</given-names></name><name name-style="western"><surname>Towers</surname><given-names>C.G.</given-names></name><name name-style="western"><surname>Drasin</surname><given-names>D.J.</given-names></name><name name-style="western"><surname>Oliphant</surname><given-names>M.U.J.</given-names></name><name name-style="western"><surname>Andrysik</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Hotz</surname><given-names>T.J.</given-names></name><name name-style="western"><surname>Vartuli</surname><given-names>R.L.</given-names></name><name name-style="western"><surname>Linklater</surname><given-names>E.S.</given-names></name><name name-style="western"><surname>Pandey</surname><given-names>A.</given-names></name><name name-style="western"><surname>Khanal</surname><given-names>S.</given-names></name><etal/></person-group><article-title>The miR-106b-25 Cluster Mediates Breast Tumor Initiation through Activation of NOTCH1 via Direct Repression of NEDD4L</article-title><source>Oncogene</source><year>2018</year><volume>37</volume><fpage>3879</fpage><lpage>3893</lpage><pub-id pub-id-type="doi">10.1038/s41388-018-0239-7</pub-id><pub-id pub-id-type="pmid">29662198</pub-id><pub-id pub-id-type="pmcid">PMC6043359</pub-id></element-citation></ref><ref id="B22-ijms-26-08618"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>El Zaiat</surname><given-names>R.S.</given-names></name><name name-style="western"><surname>Soliman</surname><given-names>M.A.E.-R.</given-names></name><name name-style="western"><surname>Ahmedy</surname><given-names>I.A.</given-names></name><name name-style="western"><surname>Alhanafy</surname><given-names>A.M.</given-names></name><name name-style="western"><surname>Genena</surname><given-names>D.E.</given-names></name><name name-style="western"><surname>Mansour</surname><given-names>M.M.</given-names></name></person-group><article-title>The Prognostic Value of the miR-106b &#8764; 25 Cluster in Chronic Lymphocytic Leukemia</article-title><source>Hum. Gene</source><year>2025</year><volume>44</volume><fpage>201407</fpage><pub-id pub-id-type="doi">10.1016/j.humgen.2025.201407</pub-id></element-citation></ref><ref id="B23-ijms-26-08618"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yu</surname><given-names>S.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>G.</given-names></name><name name-style="western"><surname>Shi</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>H.</given-names></name><name name-style="western"><surname>Zheng</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>Y.</given-names></name></person-group><article-title>MCMs in Cancer: Prognostic Potential and Mechanisms</article-title><source>Anal. Cell. Pathol.</source><year>2020</year><volume>2020</volume><fpage>3750294</fpage><pub-id pub-id-type="doi">10.1155/2020/3750294</pub-id><pub-id pub-id-type="pmcid">PMC7023756</pub-id><pub-id pub-id-type="pmid">32089988</pub-id></element-citation></ref><ref id="B24-ijms-26-08618"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bogus&#322;awska</surname><given-names>J.</given-names></name><name name-style="western"><surname>Pop&#322;awski</surname><given-names>P.</given-names></name><name name-style="western"><surname>Alseekh</surname><given-names>S.</given-names></name><name name-style="western"><surname>Koblowska</surname><given-names>M.</given-names></name><name name-style="western"><surname>Iwanicka-Nowicka</surname><given-names>R.</given-names></name><name name-style="western"><surname>Rybicka</surname><given-names>B.</given-names></name><name name-style="western"><surname>K&#281;dzierska</surname><given-names>H.</given-names></name><name name-style="western"><surname>G&#322;uchowska</surname><given-names>K.</given-names></name><name name-style="western"><surname>Hanusek</surname><given-names>K.</given-names></name><name name-style="western"><surname>Ta&#324;ski</surname><given-names>Z.</given-names></name><etal/></person-group><article-title>MicroRNA-Mediated Metabolic Reprograming in Renal Cancer</article-title><source>Cancers</source><year>2019</year><volume>11</volume><elocation-id>1825</elocation-id><pub-id pub-id-type="doi">10.3390/cancers11121825</pub-id><pub-id pub-id-type="pmid">31756931</pub-id><pub-id pub-id-type="pmcid">PMC6966432</pub-id></element-citation></ref><ref id="B25-ijms-26-08618"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mehlich</surname><given-names>D.</given-names></name><name name-style="western"><surname>Garbicz</surname><given-names>F.</given-names></name><name name-style="western"><surname>W&#322;odarski</surname><given-names>P.K.</given-names></name></person-group><article-title>The Emerging Roles of the Polycistronic miR-106b&#8764;25 Cluster in Cancer&#8212;A Comprehensive Review</article-title><source>Biomed. Pharmacother.</source><year>2018</year><volume>107</volume><fpage>1183</fpage><lpage>1195</lpage><pub-id pub-id-type="doi">10.1016/j.biopha.2018.08.097</pub-id><pub-id pub-id-type="pmid">30257332</pub-id></element-citation></ref><ref id="B26-ijms-26-08618"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Enkhnaran</surname><given-names>B.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>G.-C.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>N.-P.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>H.-N.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>H.</given-names></name><name name-style="western"><surname>Xuan</surname><given-names>S.</given-names></name><name name-style="western"><surname>Yu</surname><given-names>X.-N.</given-names></name><name name-style="western"><surname>Song</surname><given-names>G.-Q.</given-names></name><name name-style="western"><surname>Shen</surname><given-names>X.-Z.</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>J.-M.</given-names></name><etal/></person-group><article-title>microRNA-106b-5p Promotes Cell Growth and Sensitizes Chemosensitivity to Sorafenib by Targeting the BTG3/Bcl-xL/P27 Signaling Pathway in Hepatocellular Carcinoma</article-title><source>J. Oncol.</source><year>2022</year><volume>2022</volume><fpage>1971559</fpage><pub-id pub-id-type="doi">10.1155/2022/1971559</pub-id><pub-id pub-id-type="pmid">35342408</pub-id><pub-id pub-id-type="pmcid">PMC8947873</pub-id></element-citation></ref><ref id="B27-ijms-26-08618"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hussen</surname><given-names>B.M.</given-names></name><name name-style="western"><surname>Abdullah</surname><given-names>S.R.</given-names></name><name name-style="western"><surname>Rasul</surname><given-names>M.F.</given-names></name><name name-style="western"><surname>Jawhar</surname><given-names>Z.H.</given-names></name><name name-style="western"><surname>Faraj</surname><given-names>G.S.H.</given-names></name><name name-style="western"><surname>Kiani</surname><given-names>A.</given-names></name><name name-style="western"><surname>Taheri</surname><given-names>M.</given-names></name></person-group><article-title>MiRNA-93: A Novel Signature in Human Disorders and Drug Resistance</article-title><source>Cell Commun. Signal.</source><year>2023</year><volume>21</volume><fpage>79</fpage><pub-id pub-id-type="doi">10.1186/s12964-023-01106-3</pub-id><pub-id pub-id-type="pmid">37076893</pub-id><pub-id pub-id-type="pmcid">PMC10114484</pub-id></element-citation></ref><ref id="B28-ijms-26-08618"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Selvan</surname><given-names>T.G.</given-names></name><name name-style="western"><surname>Gollapalli</surname><given-names>P.</given-names></name><name name-style="western"><surname>Kumar</surname><given-names>S.H.S.</given-names></name><name name-style="western"><surname>Ghate</surname><given-names>S.D.</given-names></name></person-group><article-title>Early Diagnostic and Prognostic Biomarkers for Gastric Cancer: Systems-Level Molecular Basis of Subsequent Alterations in Gastric Mucosa from Chronic Atrophic Gastritis to Gastric Cancer</article-title><source>J. Genet. Eng. Biotechnol.</source><year>2023</year><volume>21</volume><elocation-id>86</elocation-id><pub-id pub-id-type="doi">10.1186/s43141-023-00539-0</pub-id><pub-id pub-id-type="pmid">37594635</pub-id><pub-id pub-id-type="pmcid">PMC10439097</pub-id></element-citation></ref><ref id="B29-ijms-26-08618"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>B.</given-names></name><name name-style="western"><surname>Tu</surname><given-names>S.</given-names></name><name name-style="western"><surname>Yuan</surname><given-names>H.</given-names></name></person-group><article-title>miR-25-3p Serves as an Oncogenic in Colorectal Cancer Cells by Regulating the Ubiquitin Ligase FBXW7 Function</article-title><source>Oncol. Rep.</source><year>2024</year><volume>52</volume><fpage>1</fpage><lpage>12</lpage><pub-id pub-id-type="doi">10.3892/or.2024.8812</pub-id><pub-id pub-id-type="pmcid">PMC11450686</pub-id><pub-id pub-id-type="pmid">39329268</pub-id></element-citation></ref><ref id="B30-ijms-26-08618"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lin</surname><given-names>Y.-F.</given-names></name><name name-style="western"><surname>Chou</surname><given-names>J.-L.</given-names></name><name name-style="western"><surname>Chang</surname><given-names>J.-S.</given-names></name><name name-style="western"><surname>Chiu</surname><given-names>I.-J.</given-names></name><name name-style="western"><surname>Chiu</surname><given-names>H.-W.</given-names></name><name name-style="western"><surname>Lin</surname><given-names>Y.-F.</given-names></name></person-group><article-title>Dysregulation of the miR-25-IMPA2 Axis Promotes Metastatic Progression in Clear Cell Renal Cell Carcinoma</article-title><source>EBioMedicine</source><year>2019</year><volume>45</volume><fpage>220</fpage><lpage>230</lpage><pub-id pub-id-type="doi">10.1016/j.ebiom.2019.06.006</pub-id><pub-id pub-id-type="pmid">31202813</pub-id><pub-id pub-id-type="pmcid">PMC6642077</pub-id></element-citation></ref><ref id="B31-ijms-26-08618"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>L.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>G.</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>X.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>H.</given-names></name><name name-style="western"><surname>Bai</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Sun</surname><given-names>P.</given-names></name><name name-style="western"><surname>Peng</surname><given-names>L.</given-names></name><name name-style="western"><surname>Wei</surname><given-names>W.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>G.</given-names></name><etal/></person-group><article-title>miR-93-3p Inhibition Suppresses Clear Cell Renal Cell Carcinoma Proliferation, Metastasis and Invasion</article-title><source>Oncotarget</source><year>2017</year><volume>8</volume><fpage>82824</fpage><lpage>82834</lpage><pub-id pub-id-type="doi">10.18632/oncotarget.20458</pub-id><pub-id pub-id-type="pmid">29137305</pub-id><pub-id pub-id-type="pmcid">PMC5669931</pub-id></element-citation></ref><ref id="B32-ijms-26-08618"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cao</surname><given-names>P.</given-names></name><name name-style="western"><surname>Gu</surname><given-names>J.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>M.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>M.</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>X.</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>S.</given-names></name><name name-style="western"><surname>Gao</surname><given-names>X.</given-names></name><name name-style="western"><surname>Li</surname><given-names>S.</given-names></name></person-group><article-title>BRMS1L Confers Anticancer Activity in Non-Small Cell Lung Cancer by Transcriptionally Inducing a Redox Imbalance in the GPX2-ROS Pathway</article-title><source>Transl. Oncol.</source><year>2024</year><volume>41</volume><fpage>101870</fpage><pub-id pub-id-type="doi">10.1016/j.tranon.2023.101870</pub-id><pub-id pub-id-type="pmid">38262108</pub-id><pub-id pub-id-type="pmcid">PMC10832508</pub-id></element-citation></ref><ref id="B33-ijms-26-08618"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yang</surname><given-names>H.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>X.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>M.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>X.</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>Y.</given-names></name></person-group><article-title>NFIB Promotes the Progression of Gastric Cancer by Upregulating circMAP7D1 to Stabilize HER2 mRNA</article-title><source>Mol. Med. Rep.</source><year>2021</year><volume>23</volume><fpage>269</fpage><pub-id pub-id-type="doi">10.3892/mmr.2021.11908</pub-id><pub-id pub-id-type="pmid">33576439</pub-id><pub-id pub-id-type="pmcid">PMC7893781</pub-id></element-citation></ref><ref id="B34-ijms-26-08618"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hong</surname><given-names>H.</given-names></name><name name-style="western"><surname>Shi</surname><given-names>X.</given-names></name><name name-style="western"><surname>Ou</surname><given-names>W.</given-names></name><name name-style="western"><surname>Ou</surname><given-names>P.</given-names></name></person-group><article-title>Prognostic Biomarker CPEB3 and Its Associations with Immune Infiltration in Clear Cell Renal Cell Carcinoma</article-title><source>Biomed. Rep.</source><year>2024</year><volume>20</volume><elocation-id>63</elocation-id><pub-id pub-id-type="doi">10.3892/br.2024.1751</pub-id><pub-id pub-id-type="pmid">38476610</pub-id><pub-id pub-id-type="pmcid">PMC10928475</pub-id></element-citation></ref><ref id="B35-ijms-26-08618"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kim</surname><given-names>H.-Y.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>Y.-M.</given-names></name><name name-style="western"><surname>Hong</surname><given-names>S.</given-names></name></person-group><article-title>DNAJB9 Suppresses the Metastasis of Triple-Negative Breast Cancer by Promoting FBXO45-Mediated Degradation of ZEB1</article-title><source>Cell Death Dis.</source><year>2021</year><volume>12</volume><fpage>461</fpage><pub-id pub-id-type="doi">10.1038/s41419-021-03757-x</pub-id><pub-id pub-id-type="pmid">33966034</pub-id><pub-id pub-id-type="pmcid">PMC8106677</pub-id></element-citation></ref><ref id="B36-ijms-26-08618"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yao</surname><given-names>F.</given-names></name><name name-style="western"><surname>Kong</surname><given-names>D.</given-names></name></person-group><article-title>Identification of Kinesin Family Member 3B (KIF3B) as a Molecular Target for Gastric Cancer</article-title><source>Kaohsiung J. Med. Sci.</source><year>2020</year><volume>36</volume><fpage>515</fpage><lpage>522</lpage><pub-id pub-id-type="doi">10.1002/kjm2.12206</pub-id><pub-id pub-id-type="pmid">32237034</pub-id><pub-id pub-id-type="pmcid">PMC11896200</pub-id></element-citation></ref><ref id="B37-ijms-26-08618"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rizzo</surname><given-names>S.</given-names></name><name name-style="western"><surname>Sikorski</surname><given-names>E.</given-names></name><name name-style="western"><surname>Park</surname><given-names>S.</given-names></name><name name-style="western"><surname>Im</surname><given-names>W.</given-names></name><name name-style="western"><surname>Vasquez-Montes</surname><given-names>V.</given-names></name><name name-style="western"><surname>Ladokhin</surname><given-names>A.S.</given-names></name><name name-style="western"><surname>Th&#233;venin</surname><given-names>D.</given-names></name></person-group><article-title>Promoting the Activity of a Receptor Tyrosine Phosphatase with a Novel pH-responsive Transmembrane Agonist Inhibits Cancer-associated Phenotypes</article-title><source>Protein Sci.</source><year>2023</year><volume>32</volume><fpage>e4742</fpage><pub-id pub-id-type="doi">10.1002/pro.4742</pub-id><pub-id pub-id-type="pmid">37515426</pub-id><pub-id pub-id-type="pmcid">PMC10461461</pub-id></element-citation></ref><ref id="B38-ijms-26-08618"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Girgis</surname><given-names>A.H.</given-names></name><name name-style="western"><surname>Iakovlev</surname><given-names>V.V.</given-names></name><name name-style="western"><surname>Beheshti</surname><given-names>B.</given-names></name><name name-style="western"><surname>Bayani</surname><given-names>J.</given-names></name><name name-style="western"><surname>Squire</surname><given-names>J.A.</given-names></name><name name-style="western"><surname>Bui</surname><given-names>A.</given-names></name><name name-style="western"><surname>Mankaruos</surname><given-names>M.</given-names></name><name name-style="western"><surname>Youssef</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Khalil</surname><given-names>B.</given-names></name><name name-style="western"><surname>Khella</surname><given-names>H.</given-names></name><etal/></person-group><article-title>Multilevel Whole-Genome Analysis Reveals Candidate Biomarkers in Clear Cell Renal Cell Carcinoma</article-title><source>Cancer Res.</source><year>2012</year><volume>72</volume><fpage>5273</fpage><lpage>5284</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-12-0656</pub-id><pub-id pub-id-type="pmid">22926558</pub-id></element-citation></ref><ref id="B39-ijms-26-08618"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>H.</given-names></name><name name-style="western"><surname>Sun</surname><given-names>C.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>X.</given-names></name></person-group><article-title>Exploring the Molecular Landscape of Follicular Lymphoma Histologic Grading: Insights from Genomic and Transcriptome Analyses</article-title><source>Blood</source><year>2024</year><volume>144</volume><fpage>6214</fpage><pub-id pub-id-type="doi">10.1182/blood-2024-201527</pub-id></element-citation></ref><ref id="B40-ijms-26-08618"><label>40.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ren</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Xiong</surname><given-names>W.</given-names></name><name name-style="western"><surname>Feng</surname><given-names>C.</given-names></name><name name-style="western"><surname>Yu</surname><given-names>D.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>X.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Yu</surname><given-names>S.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>H.</given-names></name><name name-style="western"><surname>Huo</surname><given-names>B.</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>H.</given-names></name><etal/></person-group><article-title>Multi-Omics Insights into the Molecular Signature and Prognosis of Hypopharyngeal Squamous Cell Carcinoma</article-title><source>Commun. Biol.</source><year>2025</year><volume>8</volume><elocation-id>370</elocation-id><pub-id pub-id-type="doi">10.1038/s42003-025-07700-0</pub-id><pub-id pub-id-type="pmid">40044946</pub-id><pub-id pub-id-type="pmcid">PMC11882983</pub-id></element-citation></ref><ref id="B41-ijms-26-08618"><label>41.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ren</surname><given-names>B.</given-names></name><name name-style="western"><surname>Yu</surname><given-names>G.</given-names></name><name name-style="western"><surname>Tseng</surname><given-names>G.C.</given-names></name><name name-style="western"><surname>Cieply</surname><given-names>K.</given-names></name><name name-style="western"><surname>Gavel</surname><given-names>T.</given-names></name><name name-style="western"><surname>Nelson</surname><given-names>J.</given-names></name><name name-style="western"><surname>Michalopoulos</surname><given-names>G.</given-names></name><name name-style="western"><surname>Yu</surname><given-names>Y.P.</given-names></name><name name-style="western"><surname>Luo</surname><given-names>J.-H.</given-names></name></person-group><article-title>MCM7 Amplification and Overexpression Are Associated with Prostate Cancer Progression</article-title><source>Oncogene</source><year>2006</year><volume>25</volume><fpage>1090</fpage><lpage>1098</lpage><pub-id pub-id-type="doi">10.1038/sj.onc.1209134</pub-id><pub-id pub-id-type="pmid">16247466</pub-id></element-citation></ref><ref id="B42-ijms-26-08618"><label>42.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>X.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Song</surname><given-names>S.</given-names></name><name name-style="western"><surname>Feng</surname><given-names>L.</given-names></name><name name-style="western"><surname>Shi</surname><given-names>C.</given-names></name></person-group><article-title>The Alterations and Potential Roles of MCMs in Breast Cancer</article-title><source>J. Oncol.</source><year>2021</year><volume>2021</volume><fpage>7928937</fpage><pub-id pub-id-type="doi">10.1155/2021/7928937</pub-id><pub-id pub-id-type="pmid">34475953</pub-id><pub-id pub-id-type="pmcid">PMC8407980</pub-id></element-citation></ref><ref id="B43-ijms-26-08618"><label>43.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lashen</surname><given-names>A.G.</given-names></name><name name-style="western"><surname>Toss</surname><given-names>M.S.</given-names></name><name name-style="western"><surname>Rutland</surname><given-names>C.S.</given-names></name><name name-style="western"><surname>Green</surname><given-names>A.R.</given-names></name><name name-style="western"><surname>Mongan</surname><given-names>N.P.</given-names></name><name name-style="western"><surname>Rakha</surname><given-names>E.</given-names></name></person-group><article-title>Prognostic and Clinical Significance of the Proliferation Marker MCM7 in Breast Cancer</article-title><source>Pathobiology</source><year>2024</year><volume>92</volume><fpage>18</fpage><lpage>27</lpage><pub-id pub-id-type="doi">10.1159/000540790</pub-id><pub-id pub-id-type="pmid">39191229</pub-id><pub-id pub-id-type="pmcid">PMC11797933</pub-id></element-citation></ref><ref id="B44-ijms-26-08618"><label>44.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Qiu</surname><given-names>Y.-T.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>W.-J.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>B.</given-names></name><name name-style="western"><surname>Mei</surname><given-names>L.-L.</given-names></name><name name-style="western"><surname>Shi</surname><given-names>Z.-Z.</given-names></name></person-group><article-title>MCM7 Amplification and Overexpression Promote Cell Proliferation, Colony Formation and Migration in Esophageal Squamous Cell Carcinoma by Activating the AKT1/mTOR Signaling Pathway</article-title><source>Oncol. Rep.</source><year>2017</year><volume>37</volume><fpage>3590</fpage><lpage>3596</lpage><comment>Erratum in <italic toggle="yes">Oncol. Rep.</italic><bold>2025</bold>, <italic toggle="yes">53</italic>, 65</comment><pub-id pub-id-type="doi">10.3892/or.2017.5614</pub-id><pub-id pub-id-type="pmid">28498460</pub-id></element-citation></ref><ref id="B45-ijms-26-08618"><label>45.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Su</surname><given-names>D.</given-names></name></person-group><article-title>MCM7 Affects the Cisplatin Resistance of Liver Cancer Cells and the Development of Liver Cancer by Regulating the PI3K/Akt Signaling Pathway</article-title><source>Immunopharmacol. Immunotoxicol.</source><year>2022</year><volume>44</volume><fpage>17</fpage><lpage>27</lpage><pub-id pub-id-type="doi">10.1080/08923973.2021.1991372</pub-id><pub-id pub-id-type="pmid">34821526</pub-id></element-citation></ref><ref id="B46-ijms-26-08618"><label>46.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bryant</surname><given-names>V.L.</given-names></name><name name-style="western"><surname>Elias</surname><given-names>R.M.</given-names></name><name name-style="western"><surname>McCarthy</surname><given-names>S.M.</given-names></name><name name-style="western"><surname>Yeatman</surname><given-names>T.J.</given-names></name><name name-style="western"><surname>Alexandrow</surname><given-names>M.G.</given-names></name></person-group><article-title>Suppression of Reserve MCM Complexes Chemosensitizes to Gemcitabine and 5-Fluorouracil</article-title><source>Mol. Cancer Res.</source><year>2015</year><volume>13</volume><fpage>1296</fpage><lpage>1305</lpage><pub-id pub-id-type="doi">10.1158/1541-7786.MCR-14-0464</pub-id><pub-id pub-id-type="pmid">26063742</pub-id><pub-id pub-id-type="pmcid">PMC4573356</pub-id></element-citation></ref><ref id="B47-ijms-26-08618"><label>47.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liang</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Li</surname><given-names>W.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>J.</given-names></name><name name-style="western"><surname>Li</surname><given-names>J.</given-names></name><name name-style="western"><surname>He</surname><given-names>F.</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>L.</given-names></name><name name-style="western"><surname>Li</surname><given-names>P.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>B.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Y.</given-names></name><etal/></person-group><article-title>Simvastatin Suppresses the DNA Replication Licensing Factor MCM7 and Inhibits the Growth of Tamoxifen-Resistant Breast Cancer Cells</article-title><source>Sci. Rep.</source><year>2017</year><volume>7</volume><elocation-id>41776</elocation-id><pub-id pub-id-type="doi">10.1038/srep41776</pub-id><pub-id pub-id-type="pmid">28150753</pub-id><pub-id pub-id-type="pmcid">PMC5288718</pub-id></element-citation></ref><ref id="B48-ijms-26-08618"><label>48.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhong</surname><given-names>H.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>B.</given-names></name><name name-style="western"><surname>Neves</surname><given-names>H.</given-names></name><name name-style="western"><surname>Xing</surname><given-names>J.</given-names></name><name name-style="western"><surname>Ye</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Lin</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Zhuang</surname><given-names>G.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>S.-D.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Kwok</surname><given-names>H.F.</given-names></name></person-group><article-title>Expression of Minichromosome Maintenance Genes in Renal Cell Carcinoma</article-title><source>Cancer Manag. Res.</source><year>2017</year><volume>9</volume><fpage>637</fpage><lpage>647</lpage><pub-id pub-id-type="doi">10.2147/CMAR.S146528</pub-id><pub-id pub-id-type="pmid">29180899</pub-id><pub-id pub-id-type="pmcid">PMC5697450</pub-id></element-citation></ref><ref id="B49-ijms-26-08618"><label>49.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>B.</given-names></name><name name-style="western"><surname>Xiao</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Li</surname><given-names>H.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>A.</given-names></name><name name-style="western"><surname>Meng</surname><given-names>L.</given-names></name><name name-style="western"><surname>Feng</surname><given-names>L.</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Ni</surname><given-names>X.</given-names></name><name name-style="western"><surname>Fan</surname><given-names>B.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>X.</given-names></name><etal/></person-group><article-title>Identification and Verification of Biomarker in Clear Cell Renal Cell Carcinoma via Bioinformatics and Neural Network Model</article-title><source>BioMed Res. Int.</source><year>2020</year><volume>2020</volume><fpage>6954793</fpage><pub-id pub-id-type="doi">10.1155/2020/6954793</pub-id><pub-id pub-id-type="pmid">32626756</pub-id><pub-id pub-id-type="pmcid">PMC7317307</pub-id></element-citation></ref><ref id="B50-ijms-26-08618"><label>50.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>H.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Q.</given-names></name></person-group><article-title>MCM2-7 in Clear Cell Renal Cell Carcinoma: MCM7 Promotes Tumor Cell Proliferation</article-title><source>Front. Oncol.</source><year>2021</year><volume>11</volume><elocation-id>782755</elocation-id><pub-id pub-id-type="doi">10.3389/fonc.2021.782755</pub-id><pub-id pub-id-type="pmid">34993142</pub-id><pub-id pub-id-type="pmcid">PMC8724441</pub-id></element-citation></ref><ref id="B51-ijms-26-08618"><label>51.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Uhl&#233;n</surname><given-names>M.</given-names></name><name name-style="western"><surname>Fagerberg</surname><given-names>L.</given-names></name><name name-style="western"><surname>Hallstr&#246;m</surname><given-names>B.M.</given-names></name><name name-style="western"><surname>Lindskog</surname><given-names>C.</given-names></name><name name-style="western"><surname>Oksvold</surname><given-names>P.</given-names></name><name name-style="western"><surname>Mardinoglu</surname><given-names>A.</given-names></name><name name-style="western"><surname>Sivertsson</surname><given-names>&#197;.</given-names></name><name name-style="western"><surname>Kampf</surname><given-names>C.</given-names></name><name name-style="western"><surname>Sj&#246;stedt</surname><given-names>E.</given-names></name><name name-style="western"><surname>Asplund</surname><given-names>A.</given-names></name><etal/></person-group><article-title>Tissue-Based Map of the Human Proteome</article-title><source>Science</source><year>2015</year><volume>347</volume><fpage>1260419</fpage><pub-id pub-id-type="doi">10.1126/science.1260419</pub-id><pub-id pub-id-type="pmid">25613900</pub-id></element-citation></ref><ref id="B52-ijms-26-08618"><label>52.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zeidler</surname><given-names>M.</given-names></name><name name-style="western"><surname>H&#252;ttenhofer</surname><given-names>A.</given-names></name><name name-style="western"><surname>Kress</surname><given-names>M.</given-names></name><name name-style="western"><surname>Kummer</surname><given-names>K.K.</given-names></name></person-group><article-title>Intragenic MicroRNAs Autoregulate Their Host Genes in Both Direct and Indirect Ways&#8212;A Cross-Species Analysis</article-title><source>Cells</source><year>2020</year><volume>9</volume><elocation-id>232</elocation-id><pub-id pub-id-type="doi">10.3390/cells9010232</pub-id><pub-id pub-id-type="pmid">31963421</pub-id><pub-id pub-id-type="pmcid">PMC7016697</pub-id></element-citation></ref><ref id="B53-ijms-26-08618"><label>53.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lu</surname><given-names>J.</given-names></name><name name-style="western"><surname>Wei</surname><given-names>J.-H.</given-names></name><name name-style="western"><surname>Feng</surname><given-names>Z.-H.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>Z.-H.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Y.-Q.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Fang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Liang</surname><given-names>Y.-P.</given-names></name><name name-style="western"><surname>Cen</surname><given-names>J.-J.</given-names></name><name name-style="western"><surname>Pan</surname><given-names>Y.-H.</given-names></name><etal/></person-group><article-title>miR-106b-5p Promotes Renal Cell Carcinoma Aggressiveness and Stem-Cell-like Phenotype by Activating Wnt/&#946;-Catenin Signalling</article-title><source>Oncotarget</source><year>2017</year><volume>8</volume><fpage>21461</fpage><lpage>21471</lpage><pub-id pub-id-type="doi">10.18632/oncotarget.15591</pub-id><pub-id pub-id-type="pmid">28423523</pub-id><pub-id pub-id-type="pmcid">PMC5400598</pub-id></element-citation></ref><ref id="B54-ijms-26-08618"><label>54.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Miao</surname><given-names>L.-J.</given-names></name><name name-style="western"><surname>Yan</surname><given-names>S.</given-names></name><name name-style="western"><surname>Zhuang</surname><given-names>Q.-F.</given-names></name><name name-style="western"><surname>Mao</surname><given-names>Q.-Y.</given-names></name><name name-style="western"><surname>Xue</surname><given-names>D.</given-names></name><name name-style="western"><surname>He</surname><given-names>X.-Z.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>J.-P.</given-names></name></person-group><article-title>miR-106b Promotes Proliferation and Invasion by Targeting Capicua through MAPK Signaling in Renal Carcinoma Cancer</article-title><source>OncoTargets Ther.</source><year>2019</year><volume>12</volume><fpage>3595</fpage><lpage>3607</lpage><pub-id pub-id-type="doi">10.2147/OTT.S184674</pub-id><pub-id pub-id-type="pmid">31190862</pub-id><pub-id pub-id-type="pmcid">PMC6525582</pub-id></element-citation></ref><ref id="B55-ijms-26-08618"><label>55.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gao</surname><given-names>P.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Hou</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Li</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>H.</given-names></name></person-group><article-title>Circular RNA ITCH Is a Tumor Suppressor in Clear Cell Renal Cell Carcinoma Metastasis through miR-106b-5p/PDCD4 Axis</article-title><source>J. Immunol. Res.</source><year>2021</year><volume>2021</volume><fpage>5524344</fpage><pub-id pub-id-type="doi">10.1155/2021/5524344</pub-id><pub-id pub-id-type="pmid">33969128</pub-id><pub-id pub-id-type="pmcid">PMC8081612</pub-id></element-citation></ref><ref id="B56-ijms-26-08618"><label>56.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yang</surname><given-names>M.</given-names></name><name name-style="western"><surname>Xiao</surname><given-names>R.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>X.</given-names></name><name name-style="western"><surname>Xiong</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Duan</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Li</surname><given-names>D.</given-names></name><name name-style="western"><surname>Kan</surname><given-names>Q.</given-names></name></person-group><article-title>MiR-93-5p Regulates Tumorigenesis and Tumor Immunity by Targeting PD-L1/CCND1 in Breast Cancer</article-title><source>Ann. Transl. Med.</source><year>2022</year><volume>10</volume><fpage>203</fpage><pub-id pub-id-type="doi">10.21037/atm-22-97</pub-id><pub-id pub-id-type="pmid">35280383</pub-id><pub-id pub-id-type="pmcid">PMC8908185</pub-id></element-citation></ref><ref id="B57-ijms-26-08618"><label>57.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bustos</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Gottlieb</surname><given-names>J.</given-names></name><name name-style="western"><surname>Choe</surname><given-names>J.</given-names></name><name name-style="western"><surname>Suyeon</surname><given-names>R.</given-names></name><name name-style="western"><surname>Lin</surname><given-names>S.Y.</given-names></name><name name-style="western"><surname>Allen</surname><given-names>W.M.</given-names></name><name name-style="western"><surname>Krasne</surname><given-names>D.L.</given-names></name><name name-style="western"><surname>Wilson</surname><given-names>T.G.</given-names></name><name name-style="western"><surname>Hoon</surname><given-names>D.S.B.</given-names></name><name name-style="western"><surname>Linehan</surname><given-names>J.A.</given-names></name></person-group><article-title>Diagnostic miRNA Signatures in Paired Tumor, Plasma, and Urine Specimens from Renal Cell Carcinoma Patients</article-title><source>Clin. Chem.</source><year>2024</year><volume>70</volume><fpage>261</fpage><lpage>272</lpage><pub-id pub-id-type="doi">10.1093/clinchem/hvad133</pub-id><pub-id pub-id-type="pmid">37791385</pub-id></element-citation></ref><ref id="B58-ijms-26-08618"><label>58.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Li</surname><given-names>K.</given-names></name><name name-style="western"><surname>Asaduzzaman</surname><given-names>M.</given-names></name><name name-style="western"><surname>Cuella</surname><given-names>R.</given-names></name><name name-style="western"><surname>Shi</surname><given-names>H.</given-names></name><name name-style="western"><surname>Raguz</surname><given-names>S.</given-names></name><name name-style="western"><surname>Coombes</surname><given-names>R.C.</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Yag&#252;e</surname><given-names>E.</given-names></name></person-group><article-title>miR-106b~25 Cluster Regulates Multidrug Resistance in an ABC Transporter-Independent Manner via Downregulation of EP300</article-title><source>Oncol. Rep.</source><year>2016</year><volume>35</volume><fpage>1170</fpage><lpage>1178</lpage><pub-id pub-id-type="doi">10.3892/or.2015.4412</pub-id><pub-id pub-id-type="pmid">26573761</pub-id></element-citation></ref><ref id="B59-ijms-26-08618"><label>59.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Smith</surname><given-names>A.L.</given-names></name><name name-style="western"><surname>Iwanaga</surname><given-names>R.</given-names></name><name name-style="western"><surname>Drasin</surname><given-names>D.J.</given-names></name><name name-style="western"><surname>Micalizzi</surname><given-names>D.S.</given-names></name><name name-style="western"><surname>Vartuli</surname><given-names>R.L.</given-names></name><name name-style="western"><surname>Tan</surname><given-names>A.-C.</given-names></name><name name-style="western"><surname>Ford</surname><given-names>H.L.</given-names></name></person-group><article-title>The miR-106b-25 Cluster Targets Smad7, Activates TGF-&#946; Signaling, and Induces EMT and Tumor Initiating Cell Characteristics Downstream of Six1 in Human Breast Cancer</article-title><source>Oncogene</source><year>2012</year><volume>31</volume><fpage>5162</fpage><lpage>5171</lpage><pub-id pub-id-type="doi">10.1038/onc.2012.11</pub-id><pub-id pub-id-type="pmid">22286770</pub-id><pub-id pub-id-type="pmcid">PMC3342483</pub-id></element-citation></ref><ref id="B60-ijms-26-08618"><label>60.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Savita</surname><given-names>U.</given-names></name><name name-style="western"><surname>Karunagaran</surname><given-names>D.</given-names></name></person-group><article-title>MicroRNA-106b-25 Cluster Targets &#946;-TRCP2, Increases the Expression of Snail and Enhances Cell Migration and Invasion in H1299 (Non Small Cell Lung Cancer) Cells</article-title><source>Biochem. Biophys. Res. Commun.</source><year>2013</year><volume>434</volume><fpage>841</fpage><lpage>847</lpage><pub-id pub-id-type="doi">10.1016/j.bbrc.2013.04.025</pub-id><pub-id pub-id-type="pmid">23611780</pub-id></element-citation></ref><ref id="B61-ijms-26-08618"><label>61.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>M.</given-names></name><name name-style="western"><surname>Xiao</surname><given-names>F.</given-names></name><name name-style="western"><surname>Li</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>X.</given-names></name><name name-style="western"><surname>Xing</surname><given-names>W.</given-names></name><name name-style="western"><surname>Yuan</surname><given-names>W.</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>Y.</given-names></name></person-group><article-title>MiR-106b-25 Promotes Chemoresistance in Acute Myeloid Leukemia Via Abolishing Multiple Apoptotic Pathways</article-title><source>Blood</source><year>2021</year><volume>138</volume><fpage>4341</fpage><pub-id pub-id-type="doi">10.1182/blood-2021-152517</pub-id></element-citation></ref><ref id="B62-ijms-26-08618"><label>62.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lo Sardo</surname><given-names>F.</given-names></name><name name-style="western"><surname>Forcato</surname><given-names>M.</given-names></name><name name-style="western"><surname>Sacconi</surname><given-names>A.</given-names></name><name name-style="western"><surname>Capaci</surname><given-names>V.</given-names></name><name name-style="western"><surname>Zanconato</surname><given-names>F.</given-names></name><name name-style="western"><surname>Di Agostino</surname><given-names>S.</given-names></name><name name-style="western"><surname>Del Sal</surname><given-names>G.</given-names></name><name name-style="western"><surname>Pandolfi</surname><given-names>P.P.</given-names></name><name name-style="western"><surname>Strano</surname><given-names>S.</given-names></name><name name-style="western"><surname>Bicciato</surname><given-names>S.</given-names></name><etal/></person-group><article-title><italic toggle="yes">MCM7</italic> and Its Hosted miR-25, 93 and 106b Cluster Elicit YAP/TAZ Oncogenic Activity in Lung Cancer</article-title><source>Carcinogenesis</source><year>2017</year><volume>38</volume><fpage>64</fpage><lpage>75</lpage><pub-id pub-id-type="doi">10.1093/carcin/bgw110</pub-id><pub-id pub-id-type="pmid">27797825</pub-id><pub-id pub-id-type="pmcid">PMC6276925</pub-id></element-citation></ref><ref id="B63-ijms-26-08618"><label>63.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gruszka</surname><given-names>R.</given-names></name><name name-style="western"><surname>Zakrzewska</surname><given-names>M.</given-names></name></person-group><article-title>The Oncogenic Relevance of miR-17-92 Cluster and Its Paralogous miR-106b-25 and miR-106a-363 Clusters in Brain Tumors</article-title><source>Int. J. Mol. Sci.</source><year>2018</year><volume>19</volume><elocation-id>879</elocation-id><pub-id pub-id-type="doi">10.3390/ijms19030879</pub-id><pub-id pub-id-type="pmid">29547527</pub-id><pub-id pub-id-type="pmcid">PMC5877740</pub-id></element-citation></ref><ref id="B64-ijms-26-08618"><label>64.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shu</surname><given-names>J.</given-names></name><name name-style="western"><surname>Silva</surname><given-names>B.V.R.E.</given-names></name><name name-style="western"><surname>Gao</surname><given-names>T.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Cui</surname><given-names>J.</given-names></name></person-group><article-title>Dynamic and Modularized MicroRNA Regulation and Its Implication in Human Cancers</article-title><source>Sci. Rep.</source><year>2017</year><volume>7</volume><elocation-id>13356</elocation-id><pub-id pub-id-type="doi">10.1038/s41598-017-13470-5</pub-id><pub-id pub-id-type="pmid">29042600</pub-id><pub-id pub-id-type="pmcid">PMC5645395</pub-id></element-citation></ref><ref id="B65-ijms-26-08618"><label>65.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Homberg</surname><given-names>N.</given-names></name><name name-style="western"><surname>Galv&#227;o Ferrarini</surname><given-names>M.</given-names></name><name name-style="western"><surname>Gaspin</surname><given-names>C.</given-names></name><name name-style="western"><surname>Sagot</surname><given-names>M.-F.</given-names></name></person-group><article-title>MicroRNA Target Identification: Revisiting Accessibility and Seed Anchoring</article-title><source>Genes.</source><year>2023</year><volume>14</volume><elocation-id>664</elocation-id><pub-id pub-id-type="doi">10.3390/genes14030664</pub-id><pub-id pub-id-type="pmid">36980936</pub-id><pub-id pub-id-type="pmcid">PMC10048102</pub-id></element-citation></ref><ref id="B66-ijms-26-08618"><label>66.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fischer</surname><given-names>S.</given-names></name><name name-style="western"><surname>Handrick</surname><given-names>R.</given-names></name><name name-style="western"><surname>Aschrafi</surname><given-names>A.</given-names></name><name name-style="western"><surname>Otte</surname><given-names>K.</given-names></name></person-group><article-title>Unveiling the Principle of microRNA-Mediated Redundancy in Cellular Pathway Regulation</article-title><source>RNA Biol.</source><year>2015</year><volume>12</volume><fpage>238</fpage><lpage>247</lpage><pub-id pub-id-type="doi">10.1080/15476286.2015.1017238</pub-id><pub-id pub-id-type="pmid">25826657</pub-id><pub-id pub-id-type="pmcid">PMC4615785</pub-id></element-citation></ref><ref id="B67-ijms-26-08618"><label>67.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cen</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Gong</surname><given-names>C.</given-names></name><name name-style="western"><surname>Li</surname><given-names>J.</given-names></name><name name-style="western"><surname>Liang</surname><given-names>G.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Luo</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Lin</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Shi</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Li</surname><given-names>J.</given-names></name><name name-style="western"><surname>Fang</surname><given-names>X.</given-names></name></person-group><article-title>BRMS1L Inhibits Bone Metastasis of Breast Cancer Cells through Epigenetic Silence of CXCR4</article-title><source>J. Clin. Oncol.</source><year>2021</year><volume>39</volume><elocation-id>e13002</elocation-id><pub-id pub-id-type="doi">10.1200/JCO.2021.39.15_suppl.e13002</pub-id></element-citation></ref><ref id="B68-ijms-26-08618"><label>68.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gong</surname><given-names>C.</given-names></name><name name-style="western"><surname>Qu</surname><given-names>S.</given-names></name><name name-style="western"><surname>Lv</surname><given-names>X.-B.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>B.</given-names></name><name name-style="western"><surname>Tan</surname><given-names>W.</given-names></name><name name-style="western"><surname>Nie</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Su</surname><given-names>F.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Yao</surname><given-names>H.</given-names></name><name name-style="western"><surname>Song</surname><given-names>E.</given-names></name></person-group><article-title>BRMS1L Suppresses Breast Cancer Metastasis by Inducing Epigenetic Silence of FZD10</article-title><source>Nat. Commun.</source><year>2014</year><volume>5</volume><fpage>5406</fpage><pub-id pub-id-type="doi">10.1038/ncomms6406</pub-id><pub-id pub-id-type="pmid">25406648</pub-id></element-citation></ref><ref id="B69-ijms-26-08618"><label>69.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cao</surname><given-names>P.</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>S.</given-names></name><name name-style="western"><surname>Sun</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>N.</given-names></name><name name-style="western"><surname>Shang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Gu</surname><given-names>J.</given-names></name><name name-style="western"><surname>Li</surname><given-names>S.</given-names></name></person-group><article-title>BRMS1L Suppresses Ovarian Cancer Metastasis via Inhibition of the &#946;-Catenin-Wnt Pathway</article-title><source>Exp. Cell Res.</source><year>2018</year><volume>371</volume><fpage>214</fpage><lpage>221</lpage><pub-id pub-id-type="doi">10.1016/j.yexcr.2018.08.013</pub-id><pub-id pub-id-type="pmid">30118697</pub-id></element-citation></ref><ref id="B70-ijms-26-08618"><label>70.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Koyama</surname><given-names>R.</given-names></name><name name-style="western"><surname>Tamura</surname><given-names>M.</given-names></name><name name-style="western"><surname>Nakagaki</surname><given-names>T.</given-names></name><name name-style="western"><surname>Ohashi</surname><given-names>T.</given-names></name><name name-style="western"><surname>Idogawa</surname><given-names>M.</given-names></name><name name-style="western"><surname>Suzuki</surname><given-names>H.</given-names></name><name name-style="western"><surname>Tokino</surname><given-names>T.</given-names></name><name name-style="western"><surname>Sasaki</surname><given-names>Y.</given-names></name></person-group><article-title>Identification and Characterization of a Metastatic Suppressor BRMS1L as a Target Gene of P53</article-title><source>Cancer Sci.</source><year>2017</year><volume>108</volume><fpage>2413</fpage><lpage>2421</lpage><pub-id pub-id-type="doi">10.1111/cas.13420</pub-id><pub-id pub-id-type="pmid">29030916</pub-id><pub-id pub-id-type="pmcid">PMC5715288</pub-id></element-citation></ref><ref id="B71-ijms-26-08618"><label>71.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Perumal</surname><given-names>N.</given-names></name><name name-style="western"><surname>Gopalakrishnan</surname><given-names>P.</given-names></name><name name-style="western"><surname>Burkovetskaya</surname><given-names>M.</given-names></name><name name-style="western"><surname>Doss</surname><given-names>D.</given-names></name><name name-style="western"><surname>Dukkipati</surname><given-names>S.S.</given-names></name><name name-style="western"><surname>Kanchan</surname><given-names>R.K.</given-names></name><name name-style="western"><surname>Mahapatra</surname><given-names>S.</given-names></name></person-group><article-title>Nuclear Factor I/B: Duality in Action in Cancer Pathophysiology</article-title><source>Cancer Lett.</source><year>2025</year><volume>609</volume><fpage>217349</fpage><pub-id pub-id-type="doi">10.1016/j.canlet.2024.217349</pub-id><pub-id pub-id-type="pmid">39581218</pub-id></element-citation></ref><ref id="B72-ijms-26-08618"><label>72.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wu</surname><given-names>C.</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>X.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>W.</given-names></name><name name-style="western"><surname>Ruan</surname><given-names>T.</given-names></name><name name-style="western"><surname>Wan</surname><given-names>W.</given-names></name><name name-style="western"><surname>Tao</surname><given-names>K.</given-names></name></person-group><article-title>NFIB Promotes Cell Growth, Aggressiveness, Metastasis and EMT of Gastric Cancer through the Akt/Stat3 Signaling Pathway</article-title><source>Oncol. Rep.</source><year>2018</year><volume>40</volume><fpage>1565</fpage><lpage>1573</lpage><pub-id pub-id-type="doi">10.3892/or.2018.6574</pub-id><pub-id pub-id-type="pmid">30015981</pub-id></element-citation></ref><ref id="B73-ijms-26-08618"><label>73.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhou</surname><given-names>L.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>H.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>S.</given-names></name><name name-style="western"><surname>Lu</surname><given-names>J.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>C.</given-names></name><name name-style="western"><surname>Liao</surname><given-names>S.</given-names></name><name name-style="western"><surname>He</surname><given-names>S.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>S.</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>Z.</given-names></name></person-group><article-title>Downregulation of miR-182-5p by NFIB Promotes NAD+ Salvage Synthesis in Colorectal Cancer by Targeting NAMPT</article-title><source>Commun. Biol.</source><year>2023</year><volume>6</volume><elocation-id>775</elocation-id><pub-id pub-id-type="doi">10.1038/s42003-023-05143-z</pub-id><pub-id pub-id-type="pmid">37491379</pub-id><pub-id pub-id-type="pmcid">PMC10368701</pub-id></element-citation></ref><ref id="B74-ijms-26-08618"><label>74.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lou</surname><given-names>C.</given-names></name><name name-style="western"><surname>Shi</surname><given-names>J.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>Q.</given-names></name></person-group><article-title>Exosomal miR-626 Promotes the Malignant Behavior of Oral Cancer Cells by Targeting NFIB</article-title><source>Mol. Biol. Rep.</source><year>2022</year><volume>49</volume><fpage>4829</fpage><lpage>4840</lpage><pub-id pub-id-type="doi">10.1007/s11033-022-07336-x</pub-id><pub-id pub-id-type="pmid">35711020</pub-id></element-citation></ref><ref id="B75-ijms-26-08618"><label>75.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Vo</surname><given-names>T.M.</given-names></name><name name-style="western"><surname>Jain</surname><given-names>S.</given-names></name><name name-style="western"><surname>Burchett</surname><given-names>R.</given-names></name><name name-style="western"><surname>Monckton</surname><given-names>E.A.</given-names></name><name name-style="western"><surname>Godbout</surname><given-names>R.</given-names></name></person-group><article-title>A Positive Feedback Loop Involving Nuclear Factor IB and Calpain 1 Suppresses Glioblastoma Cell Migration</article-title><source>J. Biol. Chem.</source><year>2019</year><volume>294</volume><fpage>12638</fpage><lpage>12654</lpage><pub-id pub-id-type="doi">10.1074/jbc.RA119.008291</pub-id><pub-id pub-id-type="pmid">31262726</pub-id><pub-id pub-id-type="pmcid">PMC6709629</pub-id></element-citation></ref><ref id="B76-ijms-26-08618"><label>76.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>N.</given-names></name><name name-style="western"><surname>Yuan</surname><given-names>J.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>F.</given-names></name><name name-style="western"><surname>Wei</surname><given-names>J.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Xue</surname><given-names>M.</given-names></name><name name-style="western"><surname>Dong</surname><given-names>R.</given-names></name></person-group><article-title>NFIB Promotes the Migration and Progression of Kidney Renal Clear Cell Carcinoma by Regulating PINK1 Transcription</article-title><source>PeerJ</source><year>2021</year><volume>9</volume><fpage>e10848</fpage><pub-id pub-id-type="doi">10.7717/peerj.10848</pub-id><pub-id pub-id-type="pmid">33981484</pub-id><pub-id pub-id-type="pmcid">PMC8074839</pub-id></element-citation></ref><ref id="B77-ijms-26-08618"><label>77.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>D.</given-names></name><name name-style="western"><surname>Su</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Li</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>J.</given-names></name><name name-style="western"><surname>Jin</surname><given-names>L.</given-names></name><name name-style="western"><surname>Shi</surname><given-names>M.</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Qi</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Gui</surname><given-names>Y.</given-names></name><etal/></person-group><article-title>MicroRNA-106b Functions as an Oncogene in Renal Cell Carcinoma by Affecting Cell Proliferation, Migration and Apoptosis</article-title><source>Mol. Med. Rep.</source><year>2016</year><volume>13</volume><fpage>1420</fpage><lpage>1426</lpage><pub-id pub-id-type="doi">10.3892/mmr.2015.4656</pub-id><pub-id pub-id-type="pmid">26648244</pub-id></element-citation></ref><ref id="B78-ijms-26-08618"><label>78.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>L.-J.</given-names></name><name name-style="western"><surname>Yu</surname><given-names>J.-J.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>X.-L.</given-names></name></person-group><article-title>MicroRNA-93 Inhibits Apoptosis and Promotes Proliferation, Invasion and Migration of Renal Cell Carcinoma ACHN Cells via the TGF-&#946;/Smad Signaling Pathway by Targeting RUNX3</article-title><source>Am. J. Transl. Res.</source><year>2017</year><volume>9</volume><fpage>3499</fpage><lpage>3513</lpage><pub-id pub-id-type="pmid">28804566</pub-id><pub-id pub-id-type="pmcid">PMC5527264</pub-id></element-citation></ref><ref id="B79-ijms-26-08618"><label>79.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>G.</given-names></name><name name-style="western"><surname>Kang</surname><given-names>X.</given-names></name><name name-style="western"><surname>Guo</surname><given-names>P.</given-names></name><name name-style="western"><surname>Shang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Du</surname><given-names>R.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>X.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>L.</given-names></name><name name-style="western"><surname>Yue</surname><given-names>R.</given-names></name><name name-style="western"><surname>Kong</surname><given-names>F.</given-names></name></person-group><article-title>miR-25-3p Promotes Proliferation and Inhibits Autophagy of Renal Cells in Polycystic Kidney Mice by Regulating ATG14-Beclin 1</article-title><source>Ren. Fail.</source><year>2020</year><volume>42</volume><fpage>333</fpage><lpage>342</lpage><pub-id pub-id-type="doi">10.1080/0886022X.2020.1745236</pub-id><pub-id pub-id-type="pmid">32340512</pub-id><pub-id pub-id-type="pmcid">PMC7241494</pub-id></element-citation></ref><ref id="B80-ijms-26-08618"><label>80.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Erkan</surname><given-names>E.P.</given-names></name><name name-style="western"><surname>Str&#246;bel</surname><given-names>T.</given-names></name><name name-style="western"><surname>Lewandrowski</surname><given-names>G.</given-names></name><name name-style="western"><surname>Tannous</surname><given-names>B.</given-names></name><name name-style="western"><surname>Madlener</surname><given-names>S.</given-names></name><name name-style="western"><surname>Czech</surname><given-names>T.</given-names></name><name name-style="western"><surname>Saydam</surname><given-names>N.</given-names></name><name name-style="western"><surname>Saydam</surname><given-names>O.</given-names></name></person-group><article-title>Depletion of Minichromosome Maintenance Protein 7 Inhibits Glioblastoma Multiforme Tumor Growth in Vivo</article-title><source>Oncogene</source><year>2014</year><volume>33</volume><fpage>4778</fpage><lpage>4785</lpage><pub-id pub-id-type="doi">10.1038/onc.2013.423</pub-id><pub-id pub-id-type="pmid">24166506</pub-id></element-citation></ref><ref id="B81-ijms-26-08618"><label>81.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dell&#8217;Atti</surname><given-names>L.</given-names></name><name name-style="western"><surname>Bianchi</surname><given-names>N.</given-names></name><name name-style="western"><surname>Aguiari</surname><given-names>G.</given-names></name></person-group><article-title>New Therapeutic Interventions for Kidney Carcinoma: Looking to the Future</article-title><source>Cancers</source><year>2022</year><volume>14</volume><elocation-id>3616</elocation-id><pub-id pub-id-type="doi">10.3390/cancers14153616</pub-id><pub-id pub-id-type="pmid">35892875</pub-id><pub-id pub-id-type="pmcid">PMC9332391</pub-id></element-citation></ref><ref id="B82-ijms-26-08618"><label>82.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Choy</surname><given-names>B.</given-names></name><name name-style="western"><surname>LaLonde</surname><given-names>A.</given-names></name><name name-style="western"><surname>Que</surname><given-names>J.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>T.</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>Z.</given-names></name></person-group><article-title>MCM4 and MCM7, Potential Novel Proliferation Markers, Significantly Correlated with Ki-67, Bmi1, and Cyclin E Expression in Esophageal Adenocarcinoma, Squamous Cell Carcinoma, and Precancerous Lesions</article-title><source>Hum. Pathol.</source><year>2016</year><volume>57</volume><fpage>126</fpage><lpage>135</lpage><pub-id pub-id-type="doi">10.1016/j.humpath.2016.07.013</pub-id><pub-id pub-id-type="pmid">27476776</pub-id><pub-id pub-id-type="pmcid">PMC5250507</pub-id></element-citation></ref><ref id="B83-ijms-26-08618"><label>83.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>W.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>X.</given-names></name></person-group><article-title>Prediction of Functional microRNA Targets by Integrative Modeling of microRNA Binding and Target Expression Data</article-title><source>Genome Biol.</source><year>2019</year><volume>20</volume><elocation-id>18</elocation-id><pub-id pub-id-type="doi">10.1186/s13059-019-1629-z</pub-id><pub-id pub-id-type="pmid">30670076</pub-id><pub-id pub-id-type="pmcid">PMC6341724</pub-id></element-citation></ref><ref id="B84-ijms-26-08618"><label>84.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>X.</given-names></name></person-group><article-title>miRDB: An Online Database for Prediction of Functional microRNA Targets</article-title><source>Nucleic Acids Res.</source><year>2020</year><volume>48</volume><fpage>D127</fpage><lpage>D131</lpage><pub-id pub-id-type="doi">10.1093/nar/gkz757</pub-id><pub-id pub-id-type="pmid">31504780</pub-id><pub-id pub-id-type="pmcid">PMC6943051</pub-id></element-citation></ref><ref id="B85-ijms-26-08618"><label>85.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shirdel</surname><given-names>E.A.</given-names></name><name name-style="western"><surname>Xie</surname><given-names>W.</given-names></name><name name-style="western"><surname>Mak</surname><given-names>T.W.</given-names></name><name name-style="western"><surname>Jurisica</surname><given-names>I.</given-names></name></person-group><article-title>NAViGaTing the Micronome--Using Multiple microRNA Prediction Databases to Identify Signalling Pathway-Associated microRNAs</article-title><source>PLoS ONE</source><year>2011</year><volume>6</volume><elocation-id>e17429</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0017429</pub-id><pub-id pub-id-type="pmid">21364759</pub-id><pub-id pub-id-type="pmcid">PMC3045450</pub-id></element-citation></ref><ref id="B86-ijms-26-08618"><label>86.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tokar</surname><given-names>T.</given-names></name><name name-style="western"><surname>Pastrello</surname><given-names>C.</given-names></name><name name-style="western"><surname>Rossos</surname><given-names>A.E.M.</given-names></name><name name-style="western"><surname>Abovsky</surname><given-names>M.</given-names></name><name name-style="western"><surname>Hauschild</surname><given-names>A.-C.</given-names></name><name name-style="western"><surname>Tsay</surname><given-names>M.</given-names></name><name name-style="western"><surname>Lu</surname><given-names>R.</given-names></name><name name-style="western"><surname>Jurisica</surname><given-names>I.</given-names></name></person-group><article-title>mirDIP 4.1&#8212;Integrative Database of Human microRNA Target Predictions</article-title><source>Nucleic Acids Res.</source><year>2018</year><volume>46</volume><fpage>D360</fpage><lpage>D370</lpage><pub-id pub-id-type="doi">10.1093/nar/gkx1144</pub-id><pub-id pub-id-type="pmid">29194489</pub-id><pub-id pub-id-type="pmcid">PMC5753284</pub-id></element-citation></ref><ref id="B87-ijms-26-08618"><label>87.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lu</surname><given-names>T.-P.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>C.-Y.</given-names></name><name name-style="western"><surname>Tsai</surname><given-names>M.-H.</given-names></name><name name-style="western"><surname>Chiu</surname><given-names>Y.-C.</given-names></name><name name-style="western"><surname>Hsiao</surname><given-names>C.K.</given-names></name><name name-style="western"><surname>Lai</surname><given-names>L.-C.</given-names></name><name name-style="western"><surname>Chuang</surname><given-names>E.Y.</given-names></name></person-group><article-title>miRSystem: An Integrated System for Characterizing Enriched Functions and Pathways of MicroRNA Targets</article-title><source>PLoS ONE</source><year>2012</year><volume>7</volume><elocation-id>e42390</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0042390</pub-id><pub-id pub-id-type="pmid">22870325</pub-id><pub-id pub-id-type="pmcid">PMC3411648</pub-id></element-citation></ref><ref id="B88-ijms-26-08618"><label>88.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Agarwal</surname><given-names>V.</given-names></name><name name-style="western"><surname>Bell</surname><given-names>G.W.</given-names></name><name name-style="western"><surname>Nam</surname><given-names>J.-W.</given-names></name><name name-style="western"><surname>Bartel</surname><given-names>D.P.</given-names></name></person-group><article-title>Predicting Effective microRNA Target Sites in Mammalian mRNAs</article-title><source>eLife</source><year>2015</year><volume>4</volume><fpage>e05005</fpage><pub-id pub-id-type="doi">10.7554/eLife.05005</pub-id><pub-id pub-id-type="pmid">26267216</pub-id><pub-id pub-id-type="pmcid">PMC4532895</pub-id></element-citation></ref><ref id="B89-ijms-26-08618"><label>89.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Colaprico</surname><given-names>A.</given-names></name><name name-style="western"><surname>Silva</surname><given-names>T.C.</given-names></name><name name-style="western"><surname>Olsen</surname><given-names>C.</given-names></name><name name-style="western"><surname>Garofano</surname><given-names>L.</given-names></name><name name-style="western"><surname>Cava</surname><given-names>C.</given-names></name><name name-style="western"><surname>Garolini</surname><given-names>D.</given-names></name><name name-style="western"><surname>Sabedot</surname><given-names>T.S.</given-names></name><name name-style="western"><surname>Malta</surname><given-names>T.M.</given-names></name><name name-style="western"><surname>Pagnotta</surname><given-names>S.M.</given-names></name><name name-style="western"><surname>Castiglioni</surname><given-names>I.</given-names></name><etal/></person-group><article-title>TCGAbiolinks: An R/Bioconductor Package for Integrative Analysis of TCGA Data</article-title><source>Nucleic Acids Res.</source><year>2016</year><volume>44</volume><fpage>e71</fpage><pub-id pub-id-type="doi">10.1093/nar/gkv1507</pub-id><pub-id pub-id-type="pmid">26704973</pub-id><pub-id pub-id-type="pmcid">PMC4856967</pub-id></element-citation></ref><ref id="B90-ijms-26-08618"><label>90.</label><element-citation publication-type="book"><person-group person-group-type="author"><collab>The R Core Team</collab></person-group><source>R: A Language and Environment for Statistical Computing</source><publisher-name>R Foundation for Statistical Computing</publisher-name><publisher-loc>Vienna, Austria</publisher-loc><year>2025</year></element-citation></ref><ref id="B91-ijms-26-08618"><label>91.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Love</surname><given-names>M.I.</given-names></name><name name-style="western"><surname>Huber</surname><given-names>W.</given-names></name><name name-style="western"><surname>Anders</surname><given-names>S.</given-names></name></person-group><article-title>Moderated Estimation of Fold Change and Dispersion for RNA-Seq Data with DESeq2</article-title><source>Genome Biol.</source><year>2014</year><volume>15</volume><elocation-id>550</elocation-id><pub-id pub-id-type="doi">10.1186/s13059-014-0550-8</pub-id><pub-id pub-id-type="pmid">25516281</pub-id><pub-id pub-id-type="pmcid">PMC4302049</pub-id></element-citation></ref><ref id="B92-ijms-26-08618"><label>92.</label><element-citation publication-type="book"><person-group person-group-type="author"><name name-style="western"><surname>Wickham</surname><given-names>H.</given-names></name></person-group><article-title>Data Analysis</article-title><source>ggplot2: Elegant Graphics for Data Analysis</source><person-group person-group-type="editor"><name name-style="western"><surname>Wickham</surname><given-names>H.</given-names></name></person-group><publisher-name>Springer International Publishing</publisher-name><publisher-loc>Cham, Switzerland</publisher-loc><year>2016</year><fpage>189</fpage><lpage>201</lpage><isbn>978-3-319-24277-4</isbn></element-citation></ref><ref id="B93-ijms-26-08618"><label>93.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Vasaikar</surname><given-names>S.V.</given-names></name><name name-style="western"><surname>Straub</surname><given-names>P.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>B.</given-names></name></person-group><article-title>LinkedOmics: Analyzing Multi-Omics Data within and across 32 Cancer Types</article-title><source>Nucleic Acids Res.</source><year>2018</year><volume>46</volume><fpage>D956</fpage><lpage>D963</lpage><pub-id pub-id-type="doi">10.1093/nar/gkx1090</pub-id><pub-id pub-id-type="pmid">29136207</pub-id><pub-id pub-id-type="pmcid">PMC5753188</pub-id></element-citation></ref><ref id="B94-ijms-26-08618"><label>94.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Dou</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Da Veiga Leprevost</surname><given-names>F.</given-names></name><name name-style="western"><surname>Geffen</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Calinawan</surname><given-names>A.P.</given-names></name><name name-style="western"><surname>Aguet</surname><given-names>F.</given-names></name><name name-style="western"><surname>Akiyama</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Anand</surname><given-names>S.</given-names></name><name name-style="western"><surname>Birger</surname><given-names>C.</given-names></name><name name-style="western"><surname>Cao</surname><given-names>S.</given-names></name><etal/></person-group><article-title>Proteogenomic Data and Resources for Pan-Cancer Analysis</article-title><source>Cancer Cell</source><year>2023</year><volume>41</volume><fpage>1397</fpage><lpage>1406</lpage><pub-id pub-id-type="doi">10.1016/j.ccell.2023.06.009</pub-id><pub-id pub-id-type="pmid">37582339</pub-id><pub-id pub-id-type="pmcid">PMC10506762</pub-id></element-citation></ref><ref id="B95-ijms-26-08618"><label>95.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Piekielko-Witkowska</surname><given-names>A.</given-names></name><name name-style="western"><surname>Wiszomirska</surname><given-names>H.</given-names></name><name name-style="western"><surname>Wojcicka</surname><given-names>A.</given-names></name><name name-style="western"><surname>Poplawski</surname><given-names>P.</given-names></name><name name-style="western"><surname>Boguslawska</surname><given-names>J.</given-names></name><name name-style="western"><surname>Tanski</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Nauman</surname><given-names>A.</given-names></name></person-group><article-title>Disturbed expression of splicing factors in renal cancer affects alternative splicing of apoptosis regulators, oncogenes, and tumor suppressors</article-title><source>PLoS ONE</source><year>2010</year><volume>5</volume><elocation-id>e13690</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0013690</pub-id><pub-id pub-id-type="pmid">21082031</pub-id><pub-id pub-id-type="pmcid">PMC2972751</pub-id></element-citation></ref><ref id="B96-ijms-26-08618"><label>96.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Glenn</surname><given-names>S.T.</given-names></name><name name-style="western"><surname>Jones</surname><given-names>C.A.</given-names></name><name name-style="western"><surname>Liang</surname><given-names>P.</given-names></name><name name-style="western"><surname>Kaushik</surname><given-names>D.</given-names></name><name name-style="western"><surname>Gross</surname><given-names>K.W.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>H.L.</given-names></name></person-group><article-title>Expression profiling of archival renal tumors by quantitative PCR to validate prognostic markers</article-title><source>Biotechniques</source><year>2007</year><volume>43</volume><fpage>639</fpage><lpage>647</lpage><page-range>639&#8211;640, 642&#8211;643, 647</page-range><pub-id pub-id-type="doi">10.2144/000112562</pub-id><pub-id pub-id-type="pmid">18072593</pub-id></element-citation></ref><ref id="B97-ijms-26-08618"><label>97.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Master</surname><given-names>A.</given-names></name><name name-style="western"><surname>W&#243;jcicka</surname><given-names>A.</given-names></name><name name-style="western"><surname>Piekie&#322;ko-Witkowska</surname><given-names>A.</given-names></name><name name-style="western"><surname>Bogus&#322;awska</surname><given-names>J.</given-names></name><name name-style="western"><surname>Pop&#322;awski</surname><given-names>P.</given-names></name><name name-style="western"><surname>Ta&#324;ski</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Darras</surname><given-names>V.M.</given-names></name><name name-style="western"><surname>Williams</surname><given-names>G.R.</given-names></name><name name-style="western"><surname>Nauman</surname><given-names>A.</given-names></name></person-group><article-title>Untranslated regions of thyroid hormone receptor beta 1 mRNA are impaired in human clear cell Renal Cell Carcinoma</article-title><source>Biochim. Biophys. Acta</source><year>2010</year><volume>1802</volume><fpage>995</fpage><lpage>1005</lpage><pub-id pub-id-type="doi">10.1016/j.bbadis.2010.07.025</pub-id><pub-id pub-id-type="pmid">20691260</pub-id></element-citation></ref><ref id="B98-ijms-26-08618"><label>98.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhao</surname><given-names>F.</given-names></name><name name-style="western"><surname>Gong</surname><given-names>X.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>A.</given-names></name><name name-style="western"><surname>Lv</surname><given-names>X.</given-names></name><name name-style="western"><surname>Hu</surname><given-names>B.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>H.</given-names></name></person-group><article-title>Downregulation of Nedd4L predicts poor prognosis, promotes tumor growth and inhibits MAPK/ERK signal pathway in hepatocellular carcinoma</article-title><source>Biochem. Biophys. Res. Commun.</source><year>2018</year><volume>495</volume><fpage>1136</fpage><lpage>1143</lpage><pub-id pub-id-type="doi">10.1016/j.bbrc.2017.11.139</pub-id><pub-id pub-id-type="pmid">29175326</pub-id></element-citation></ref><ref id="B99-ijms-26-08618"><label>99.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shah</surname><given-names>K.N.</given-names></name><name name-style="western"><surname>Mehta</surname><given-names>K.R.</given-names></name><name name-style="western"><surname>Peterson</surname><given-names>D.</given-names></name><name name-style="western"><surname>Evangelista</surname><given-names>M.</given-names></name><name name-style="western"><surname>Livesey</surname><given-names>J.C.</given-names></name><name name-style="western"><surname>Faridi</surname><given-names>J.S.</given-names></name></person-group><article-title>AKT-induced tamoxifen resistance is overturned by RRM2 inhibition</article-title><source>Mol. Cancer Res.</source><year>2014</year><volume>12</volume><fpage>394</fpage><lpage>407</lpage><pub-id pub-id-type="doi">10.1158/1541-7786.MCR-13-0219</pub-id><pub-id pub-id-type="pmid">24362250</pub-id></element-citation></ref><ref id="B100-ijms-26-08618"><label>100.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Poplawski</surname><given-names>P.</given-names></name><name name-style="western"><surname>Nauman</surname><given-names>A.</given-names></name></person-group><article-title>Thyroid hormone&#8212;Triiodothyronine&#8212;Has contrary effect on proliferation of human proximal tubules cell line (HK2) and renal cancer cell lines (Caki-2, Caki-1)&#8212;Role of E2F4, E2F5 and p107, p130</article-title><source>Thyroid Res.</source><year>2008</year><volume>1</volume><fpage>5</fpage><pub-id pub-id-type="doi">10.1186/1756-6614-1-5</pub-id><pub-id pub-id-type="pmid">19014670</pub-id><pub-id pub-id-type="pmcid">PMC2583984</pub-id></element-citation></ref><ref id="B101-ijms-26-08618"><label>101.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhou</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>S.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>P.</given-names></name></person-group><article-title>Effect of Exogenous Fetuin-A on TGF-&#946;/Smad Signaling in Hepatic Stellate Cells</article-title><source>Biomed. Res. Int.</source><year>2016</year><volume>2016</volume><elocation-id>8462615</elocation-id><pub-id pub-id-type="doi">10.1155/2016/8462615</pub-id><pub-id pub-id-type="pmid">27990439</pub-id><pub-id pub-id-type="pmcid">PMC5136394</pub-id></element-citation></ref></ref-list></back><floats-group><fig position="float" id="ijms-26-08618-f001" orientation="portrait"><label>Figure 1</label><caption><p>MCM7 is overexpressed in ccRCC tissue samples. (<bold>A</bold>) <italic toggle="yes">MCM7</italic> mRNA expression was analyzed in paired human ccRCC samples from Group 1 (TNM Stages I&#8211;II; N1/T1; <italic toggle="yes">n</italic> = 29) and paired samples from Group 2 (TNM Stages III&#8211;IV; N2/T2; <italic toggle="yes">n</italic> = 29) using qPCR, with 18S rRNA as the endogenous control gene. Combined analysis of all samples (Nall/Tall, <italic toggle="yes">n</italic> = 58) is also shown. Statistical significance was determined using the Shapiro&#8211;Wilk test and the Wilcoxon signed-rank test (**** <italic toggle="yes">p</italic> &lt; 0.0001). (<bold>B</bold>) MCM7 protein level was assessed by Western blot in paired human ccRCC samples. Results from patients P1&#8211;P10 (low TNM Stages I&#8211;II, <italic toggle="yes">n</italic> = 20) and P11&#8211;P20 (high TNM Stages III&#8211;IV, <italic toggle="yes">n</italic> = 20) are shown. &#946;-actin was used as the loading control.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="ijms-26-08618-g001.jpg"/></fig><fig position="float" id="ijms-26-08618-f002" orientation="portrait"><label>Figure 2</label><caption><p>Expression of MCM7 transcript (<bold>A</bold>) and protein (<bold>B</bold>) levels across the TCGA-KIRC and CPTAC-ccRCC datasets. MCM7 expression is elevated in ccRCC at both transcriptomic (<bold>A</bold>) and proteomic (<bold>B</bold>) levels. (<bold>A</bold>) <italic toggle="yes">MCM7</italic> mRNA expression was analyzed using RNA-seq data from TCGA-KIRC. Samples were stratified into low-stage (N1/T1; N1 = 31; T1 = 294; TNM Stage I&#8211;II), high-stage (N2/T2; N2 = 27; T2 = 158; TNM Stage III&#8211;IV), and all samples combined (Nall/Tall; Nall = 72; Tall = 541). Expression values are shown as variance-stabilized transformed (VST) counts. (<bold>B</bold>) MCM7 protein levels were assessed using CPTAC-ccRCC proteomics data. Log<sub>2</sub>-transformed MS1 intensities are presented for matching sample groupings. Group 1 (Stages I&#8211;II; N1/T1; N1 = 40, T1 = 40) and Group 2 (Stages III&#8211;IV; N2/T2; N2 = 40, T2 = 40). The combined category included all tumor and normal samples (Nall/Tall; Nall = 80, Tall = 80).</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="ijms-26-08618-g002.jpg"/></fig><fig position="float" id="ijms-26-08618-f003" orientation="portrait"><label>Figure 3</label><caption><p>MCM7 inhibition reduces proliferation (<bold>A</bold>) and caspase-3/7 activity (<bold>B</bold>) in renal cancer cells. Caki-2 cells were transfected with synthetic siRNA for MCM7 (siMCM7) or a control oligonucleotide (siCTRL). Proliferation (<bold>A</bold>) and caspase 3/7 activity (<bold>B</bold>) were evaluated 72 h after transient transfection using BrdU and caspase-3/7 activity (<bold>B</bold>) assays, respectively. <italic toggle="yes">n</italic> = 4&#8211;5. Results are presented as mean &#177; SEM. Statistical analysis: Shapiro&#8211;Wilk; Mann&#8211;Whitney test. * <italic toggle="yes">p</italic> &lt; 0.05, ** <italic toggle="yes">p</italic> &lt; 0.01.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="ijms-26-08618-g003.jpg"/></fig><fig position="float" id="ijms-26-08618-f004" orientation="portrait"><label>Figure 4</label><caption><p>Aberrant expression of cancer progression&#8211;related genes in ccRCC. mRNA expression was analyzed in paired human ccRCC samples from Group 1 (TNM Stages I&#8211;II; N1/T1; <italic toggle="yes">n</italic> = 29) and paired samples from Group 2 (TNM Stages III&#8211;IV; N2/T2; <italic toggle="yes">n</italic> = 29) using qPCR, with 18S rRNA as the endogenous control gene. Combined analysis of all samples (Nall/Tall, <italic toggle="yes">n</italic> = 58) is also shown. Statistical analysis: Shapiro&#8211;Wilk test and Wilcoxon signed-rank test (* <italic toggle="yes">p</italic> &lt; 0.05, ** <italic toggle="yes">p</italic> &lt; 0.01, *** <italic toggle="yes">p</italic> &lt; 0.001, **** <italic toggle="yes">p</italic> &lt; 0.0001).</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="ijms-26-08618-g004.jpg"/></fig><fig position="float" id="ijms-26-08618-f005" orientation="portrait"><label>Figure 5</label><caption><p>Expression levels of miR-106b-25 targets across the TCGA-KIRC dataset. The mRNA expression levels of 10 predicted miR-106b-25 targets were analyzed using RNA-seq data from TCGA-KIRC. Samples were stratified into low-stage (N1/T1; N1 = 31; T1 = 294; TNM Stage I&#8211;II), high-stage (N2/T2; N2 = 27; T2 = 158; TNM Stage III&#8211;IV), and all samples combined (Nall/Tall; Nall = 72; Tall = 158). Expression values are shown as variance-stabilized transformed (VST) counts. Statistical differences between groups (N vs. T within each stage) were assessed using the Wilcoxon rank-sum test.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="ijms-26-08618-g005.jpg"/></fig><fig position="float" id="ijms-26-08618-f006" orientation="portrait"><label>Figure 6</label><caption><p>miRNAs from the miR-106b-25 cluster affect the expression of cancer progression-related genes in ccRCC. Caki-2 (<bold>A</bold>) and KIJ-265T (<bold>B</bold>) cells were transfected with synthetic miRNA mimics (for miR-25-35, 93-5p, 106b-5p, or a combination of all three: 25 + 93 + 106) or control oligonucleotides (CTRL). Gene expression was measured by the qPCR method. <italic toggle="yes">n</italic> = 3. Results are presented as mean &#177; SEM. Statistical analysis: Shapiro&#8211;Wilk; ANOVA with Dunn&#8217;s post hoc test; Kruskal&#8211;Wallis with Dunnett&#8217;s post hoc test. * <italic toggle="yes">p</italic> &lt; 0.05, ** <italic toggle="yes">p</italic> &lt; 0.01, *** <italic toggle="yes">p</italic> &lt; 0.001, **** <italic toggle="yes">p</italic> &lt; 0.0001.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="ijms-26-08618-g006.jpg"/></fig><fig position="float" id="ijms-26-08618-f007" orientation="portrait"><label>Figure 7</label><caption><p>Direct regulation of ccRCC-progression-related genes by miR-25-3p, miR-93-5p, and miR-106b-5p in ccRCC cells. Caki-2 cells were co-transfected with miRNA mimics/control oligonucleotides and constructs (<bold>A</bold>&#8211;<bold>G</bold>)/control vector (<bold>H</bold>) as indicated in the Methods section. 48 h after transfection, luciferase activity was measured and normalized to Renilla activity. <italic toggle="yes">n</italic> = 3. Data were log<sub>10</sub>-transformed. Statistical analysis: Shapiro&#8211;Wilk, <italic toggle="yes">t</italic>-test, Mann&#8211;Whitney test. * <italic toggle="yes">p</italic> &lt; 0.05, ** <italic toggle="yes">p</italic> &lt; 0.01, *** <italic toggle="yes">p</italic> &lt; 0.001, **** <italic toggle="yes">p</italic> &lt; 0.0001. The putative miRNA binding sites in the 3&#8242;UTRs of target genes, along with sequence alignments of the miRNA seed regions, are shown to the right of the corresponding graphs.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="ijms-26-08618-g007.jpg"/></fig><fig position="float" id="ijms-26-08618-f008" orientation="portrait"><label>Figure 8</label><caption><p>MCM7 and miR-106b-25 cluster alter proliferation (<bold>A</bold>) and caspase-3/7 activity (<bold>B</bold>) of RCC cells. Caki-2 and KIJ-265T cells were co-transfected with siRNA for the MCM7 gene and/or a mix of microRNA inhibitors (miR-inhibitors: 25/93/106) and/or control oligonucleotides (siCTRL, miR-inhibitor CTRL) as shown in the graph description. Cell proliferation (BrdU assay) and caspase-3/7 activity were evaluated 72 h post-transfection. Statistical analysis: ANOVA/Dunn&#8217;s test. * <italic toggle="yes">p</italic> &lt; 0.05, ** <italic toggle="yes">p</italic> &lt; 0.01.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="ijms-26-08618-g008.jpg"/></fig></floats-group></article></pmc-articleset>